Since 1960, it has been possible to remove small substances with hemodialysis using cellulosic dialysis membrane. In 1971, it was hypothesized by Babb et al. that increased removal of middle molecular uremic toxins (MMTs), range from 300 to 3,000 daltons, was important for the improvement of remaining complications such as uremic neuropathy in patients on hemodialysis. They suggested that removal of MMTs could be enhanced by increasing the dialysis hours per week and the membrane area (square-meter). Although for the next 10 years many researchers worldwide investigated the specific identity of MMTs and the clinical efficacy of their removal, no significant advances were made. In Japan in 1980, we speculated that uremic substances bigger than the MMTs suggested by Babb et al. might be relevant to the uremic symptoms observed. In conjunction with several dialyzer companies, we set out to develop new dialyzers by which considerable amounts of low molecular weight proteins and a small amount of albumin would be removed per dialysis session, similar to that observed by glomerular filtration. Clinical improvements such as renal anemia, joint pain in dialysis-related amyloidosis, pruritus, and uremic pigmentation of patients treated by these dialyzers were evaluated. Prior to, and during the development and clinical evaluation of these membrane dialyzers, we investigated their clinical significance and attempted to clarify the pathological mechanisms underlying the accumulation of middle and large molecules.
Since 1960, it has been possible to remove small substances with hemodialysis using cellulosic dialysis membrane. In 1971, it was hypothesized by Babb et al. that increased removal of middle molecular uremic toxins (MMTs), range from 300 to 3,000 daltons, was important for the improvement of remaining complications such as uremic neuropathy in patients on hemodialysis. They suggested that removal of MMTs could be enhanced by increasing the dialysis hours per week and the membrane area (square-meter). Although for the next 10 years many researchers worldwide investigated the specific identity of MMTs and the clinical efficacy of their removal, no significant advances were made. In Japan in 1980, we speculated that uremic substances bigger than the MMTs suggested by Babb et al. might be relevant to the uremic symptoms observed. In conjunction with several dialyzer companies, we set out to develop new dialyzers by which considerable amounts of low molecular weight proteins and a small amount of albumin would be removed per dialysis session, similar to that observed by glomerular filtration. Clinical improvements such as renal anemia, joint pain in dialysis-related amyloidosis, pruritus, and uremic pigmentation of patients treated by these dialyzers were evaluated. Prior to, and during the development and clinical evaluation of these membrane dialyzers, we investigated their clinical significance and attempted to clarify the pathological mechanisms underlying the accumulation of middle and large molecules.
The newly developed dialyzers were named "high-performance membrane dialyzers (HPM)" in 1985 when Gejyo et al. identified β 2 -microglobulin (β 2 -m) as the fibril protein underlying dialysisrelated amyloidosis. HPMs were approved as superior to conventional dialyzers with in vitro clearance of β 2 -m being less than 10 ml/ min, and at present, all dialyzers used in Japan are HPM dialyzers. We investigated the accumulation of protein-binding uremic toxins, such as indolic tryptophan metabolites and guanidine compounds. Prior to 1985, we had utilized circular dichroism to determine the threedimensional conformational change in uremic albumin that occurred as a result of solute-binding. α-Helical components of albumin are remarkably reduced in uremic conditions due to the binding of many uremic toxins, such as indolic compounds and methyl guanidine, to albumin. We also intended to identify the middle molecular inhibitor of erythroid colony formation by using several steps of liquid chromatography technology.
We reported the identification of a novel β 2 -m molecule in the serum of dialysis patients with β 2 -m amyloidosis, which differed from the native β 2 -m at the 17 th amino acid from the N-terminal: aspartic acid was deaminated from asparagine. Dr. Miyata, a colleague in the same research group discovered that β 2 -m was modified with advanced glycation end products, which stimulated cytokine production in the synovial tissue and bones, or in tissue of carpal tunnel syndrome.
Renal replacement therapy does not substitute for the reabsorptive, metabolic, immunomodulatory, and endocrine functions of renal tubule, and hence, many dialysis-related complications arise. To overcome this, we intended to add renal tubular metabolic functions to renal replacement therapy with the aim of improving the prognosis of acute kidney injury (AKI) patients with multiple organ dysfunction syndrome (MODS) . We produced bioartificial tubule devices, which consisted of hollow fibers lined with renal tubule cells. Expression of cytokine m RNAs in cytokine-producing cells and serum levels of inflammatory cytokines were significantly suressed during the device treatment in AKI goats with MODS, resulting in significantly improved prognosis. This technology could be applied to the treatment of chronic dialysis patients to prevent the onset and progression of long-term dialysis complications in the future. Abstracts Symposium 1
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Mortality and Cardiovascular Outcomes Related to CKD-MBD
Hirotaka Komaba
Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan
Chronic kidney disease (CKD) is a global public health problem associated with a markedly increased risk of death and cardiovascular disease. The high prevalence of cardiovascular disease in patients with CKD cannot be explained solely by traditional risk factors, and several CKD-specific risk factors have been postulated, among which mineral and bone disorder (MBD) is one of the most prominent. Since the early 1990s, numerous observational studies have shown associations between increased levels of calcium, phosphate, and parathyroid hormone (PTH) and increased mortality and cardiovascular morbidity in patients receiving hemodialysis. Several observational studies of Japanese hemodialysis patients, including an analysis of data from the nationwide registry of the Japanese Society for Dialysis Therapy (JSDT) and a report from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS), also demonstrated associations between parameters of CKD-MBD and poor clinical outcomes. A more recent prospective case-cohort study conducted in Japan, the MBD Outcomes Study for Japanese CKD Stage 5D Patients (MBD-5D), has shown that higher calcium and lower or higher phosphate levels were associated with increased all-cause and cardiovascular mortality, using marginal structural models.
These consistent results support the validity of controlling parameters of CKD-MBD, and much attention has been focused on the effects of interventions directed at CKD-MBD on patientlevel outcomes. Two recent prospective observational studies, from the Accelerated Mortality on Renal Replacement (ArMORR) and the DOPPS, have shown that the use of phosphorus binders is independently associated with improved survival among hemodialysis patients. Several observational studies also showed that treatment with vitamin D receptor activators (VDRAs) is associated with improved survival in patients on maintenance dialysis. In addition, a recent observational study in the US showed a significantly reduced risk for all-cause and cardiovascular mortality associated with cinacalcet use among hemodialysis patients treated with VDRAs. A more recent study from the MBD-5D also found a significant reduction in all-cause and cardiovascular mortality associated with consistent use of cinacalcet. Finally, a retrospective analysis of data from the JSDT demonstrated that compared with matched controls, patients undergoing parathyroidectomy (PTx) had significantly decreased all-cause and cardiovascular mortality, suggesting that PTx should be regarded not as an undesirable outcome but as a treatment option for severe secondary hyperparathyroidism.
This presentation will summarize the results of recent studies demonstrating associations between parameters of CKD-MBD or interventions directed at CKD-MBD and patient-level clinical outMice lacking Klotho (kl/kl mice) are refractory to FGF23 and unable to excrete excess Pi into urine. As a result, kl/kl mice develop Pi retention phenotypes including hyperphosphatemia and vascular calcification. In addition to these predictable phenotypes, kl/kl mice unexpectedly develop a premature aging syndrome characterized by growth arrest, cognition impairment, hearing loss, cortical osteopenia, cardiac hypertrophy, emphysematous lung, atrophy of thymus, fat, muscle, and gonads, resulting in shortened life span. These phenotypes are alleviated by resolving Pi retention with dietary or genetic interventions (e.g. low Pi diet, low vitamin D diet, knockout of vitamin D receptor, 1α-hydroxylase, or type IIa Na-dependent Pi co-transporter), indicating that the premature aging syndrome is primarily attributable to Pi retention.
Pi retention is universally observed in CKD patients. CKD patients exhibit low renal Klotho expression and high blood FGF23. They develop vascular calcification, osteopenia, cardiac hypertrophy, and hyperphosphatemia, resulting in high mortality. In addition, Pi restriction and Pi binders improve their clinical outcomes. These features are reminiscent of kl/kl mice, suggesting that CKD may be viewed as a premature aging syndrome caused by Pi overload and Klotho deficiency.
When functional nephron number decreases with CKD progression, Pi excretion per nephron must be increased to maintain Pi balance unless dietary Pi intake is reduced. This demand is met primarily by increasing FGF23. However, this is at the expense of calcitriol as FGF23 suppresses calcitriol synthesis. In fact, normal blood Pi, high FGF23, and low calcitriol are characteristic features of early stage CKD. Because calcitriol increases Klotho gene expression, low calcitriol further reduces Klotho. In addition, low calcitriol increases PTH and high PTH further stimulates FGF23. This constellation forms a self-aggravating spiral of decreased Klotho and increased FGF23. Thus, high FGF23 should be recognized as a warning of excess Pi intake relative to the remaining functional nephron number. When the nephron number is decreased to a level that fails to maintain Pi excretion in response to increased FGF23 and PTH, hyperphosphatemia ensues.
This Pi-centric view of CKD pathophysiology suggests many targets of therapeutic interventions that interrupt the vicious cycle and potentially prevent CKD progression: Parathyroidectomy and calcimimetics decrease PTH. ACE inhibitors, thiazolidinediones, and vitamin D can increase Klotho levels because Klotho expression is decreased by angiotensin II and increased by PPARγ and vitamin D receptor agonists. FGF23 antagonists will be promising reagents as they are expected not only to interrupt this vicious cycle but also to block off-target effects of FGF23 on the heart as high FGF23 can induce cardiac hypertrophy independently of Klotho. Thus, a rational therapeutic strategy deduced from this Pi-centric view of CKD is to start these interventions in combination with Pi restriction and Pi binders when blood FGF23 levels start to increase. Pre-clinical and clinical studies are necessary to verify this notion.
Emerging evidence suggests that vitamin D plays important roles in modulating cardiovascular, immunological, metabolic and other functions. However, numerous questions remain unanswered about the vitamin D-VDR axis. Current clinical practices focus on studying 25(OH)D deficiency in the blood. One important question that needs to be addressed is whether 25(OH)D is a proper marker for gauging VDR activation or not. It is well recognized that 25(OH)D is a precursor of the active form of vitamin D, calcitriol; 25(OH)D itself is not effective in activating VDR. Development of biomarkers that can measure the disturbance of VDR activation will be helpful. Although vitamin D and its analogs are potentially useful for preventing and treating various diseases, their usage at this point is still rather limited. It is partially due to the fact that there is no way to distinguish whether the lack of effect of vitamin D and its analogs in clinical studies results from inadequate activation of VDR or a general lack of efficacy. In addition, evidences are growing that metabolism of vitamin D is altered in CKD situation, in other words, the balance between CYP27A1 and CYP24 activities is disturbed. Another potential issue is that current on-the-market vitamin D analogs used to treat diseases such as secondary hyperparathyroidism, psoriasis and osteoporosis have narrow therapeutic window and considerable side effects. New vitamin D analogs that have a wider therapeutic window without the hypercalcemic and hyperphosphatemic liabilities will allow the expanded usage of the drugs into new therapeutic indications. In this session we would like to discuss which is important for patients with renal injury; correcting 25(OH)D deficiency or activating VDR directly by vitamin D analogs.
SY1-4
Pathomechanisms of Cardiovascular Calcification in CKD: Is it Reversible?
Markus Ketteler
Division of Nephrology, Klinikum Coburg, Coburg, Germany
Strong and unidirectional associations exist between the severity of cardiovascular calcifications and mortality in patients with advanced chronic kidney disease (CKD). In the past 10 years, a wealth of experimental and clinical information has been published focusing on the key pathophysiological events that might trigger the development and progression of vascular and soft-tissue calcifications. These processes involve a sensitive balance of calcification inhibition, induction and removal. comes and discuss the need for a randomized controlled trial to determine whether better management of CKD-MBD by interventions actually translates into improved clinical outcomes.
SY1-2
The Role of FGF23 Abnormalities in CKD-MBD
Mariano Rodriguez
Hospital Universitario Reina Sofia, IMIBIC, Cordoba, Spain FGF23 is one fosfatonin generated by bone cells, osteoblasts and osteocytes that acts on specific cell membrane FGFR-Klotho receptor expressed in kidney and parathyroid cells. The effects of FGF23 are: increase in phosphaturia, decreased in of 1,25(OH)2D3 production and suppression of PTH production. The production of FGF23 is increased by phosphate load, 1,25(OH)2D3 and PTH.
In CKD patients serum levels of FGF23 are increased since the earliest stages of the disease and it even precedes the elevation of PTH. The increase in FGF23 may be responsible for the early decrease in 1,25(OH)2D3 production in CKD; thus it plays a critical role in the initiation of secondary hyperparathyroidism. Based in clinical studies some authors have suggested that the reduction of phosphate may decrease FGF23 production in CKD.
Studies in experimental animals and in parathyroids from dialysis patients have shown that once parathyroid hyperplasia is established there is a reduction of parathyroid FGFR-Klotho receptor expression which makes these cells resistant to the inhibitory effect of FGF23, thus high FGF23 in CKD does not reduce PTH levels.
Recent experimental work has shown that hypocalcemia reduces FGF23 production and prevent its stimulation by a high phosphate diet. Since FGF23 reduces 1,25(OH)2D3 production a situation of calcium deficit does not allow a reduction of 1,25(OH)2D3 levels induced by FGF23. Much has been learned on FGF23 regulation during the last decade but there are still unanswered questions.
The increased in FGF23 in CKD patients has been associated to mortality, progression of renal disease, vascular calcification, poor graft survival…. These deleterious effects may be explain in part by a direct effect of FGF23 on the cardiovascular system. FGF23 directly increases left ventricular hypertrophy in experimental animals. There is a family of FGF23 receptors that can be activated by the high levels of FGF23.
Klotho molecule (soluble fraction) has a phosphaturic effect, protect vascular smooth muscle cells from calcification and it prevents acute kidney injury. We have learned that klotho expression is upregulated by vitamin D. It seems that Kidney produces most, if not all, of the available klotho and in CKD klotho production is down regulated.
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Oxidative Stress, Tissue Ischemia and Deterioration of Renal Microcirculation Elucidated with In Vivo Imaging Technique, in the Pathogenesis of Chronic Kidney Disease
Naoki Kashihara
Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan CKD is strongly associated with cardiovascular disease (CVD). Individuals with CKD are more likely to die of CVD than to develop kidney failure. Albuminuria is a strong risk factor for CVD and is prevalent in the general population and among patients with life stylerelated diseases. Epidemiological data suggest that 5-7%, of the general population have increased urinary albumin excretion.
Elucidation of phathogenetic mechanisms of albuminuria will give us better understandings of underlying mechanisms between CKD and CVD. Both glomerular hyperfiltration and endothelial dysfunction are believed to be implicated with development of albuminuria in the conditions such as diabetes, hypertension and metabolic syndrome. To elucidate the pathogenetic mechanisms of albuminuria, we have developed the novel techniques by which we could visualize the micro-circulation in the kidney using two-photon lasermicroscopy. We have also developed the novel techniques to detect reactive oxygen species (ROS) and nitric oxide (NO) simultaneously in the tissue specimen.
Using these techniques, we have found impaired bioavailability of NO and increased oxidative stress in the small arteries and glomeruli in the disease conditions. Permselectivity of macromolecules in the glomerular vascular walls were deteriorated at the same time in these conditions. Finally, we would like to show how renin angiotensin blockage by angiotensin II receptor blocker (ARB), the first choice as antihypertensive for the patient with CKD, could ameliorate endothelial dysfunction and hyperpermeability of macromolecules with the aid of these techniques.
SY2-2
The Roles of Hypoxic Responses in Macrophage Activation Hypoxia is a pathological condition in which the tissue is deprived of adequate oxygen supply. Each cell exerts its own responses to Our general perception is that soft-tissue calcification is a progressive process that may be slowed down, but never reversed. However, extraosseous calcification is likely to be a dynamic process, possibly analogous to osseous calcification, where there is continuous formation and reabsorption of calcified matrix in a healthy bone leading to complete turnover of the individual's skeletal system every 7-10 years. Therefore, one of the central questions related to extraskeletal calcification processes is whether the body may be able to regress preformed calcifications from extraosseous sites.
The ultrastructure of early calcification deposits permits the postulation of potential reversibility. Several imaging and microimaging methods (micro-CT, transmission electron microscopy, energy dispersive spectroscopy, synchrotron X-ray analyses etc.) recently revealed the presence of nanocrystals in early soft-tissue calcification. In arterial samples from dialysis patients, such microcalcifications with a core-shell structure (diameter 20-500 nm) consisting of hydroxyapatite and whitlockite were frequently found. These microcalcifications were often composed of 2-10 nm calcium phosphate nanocrystals, but also contained calcium-regulatory proteins including fetuin-A, osteopontin and matrix Gla protein (MGP). Conceptually, these calciprotein particle (CPP)-associated calcifications are not irreversible or stationary, as they may represent transport particles removing calcified debris.
One recent report studied the properties of particles in ascitic fluid from a patient with peritoneal dialysis-related calcifying peritonitis. Identified calciprotein particles were composed of fetuin-A, albumin, other acidic proteins, calcium and phosphate, with fetuin-A being indispensable for the formation and stabilization of these bodies. Another study used ultracentrifugation in order to harvest CPPlike bodies from the sera of patients on dialysis and from predialysis patients with diabetes mellitus. These particles were composed of fetuin-A, fibrinogen, fibronectin 1, and calcium, and levels seemed to increase with worsening kidney function, with the highest levels detected in patients on dialysis. Importantly, centrifugation of the sera lowered serum fetuin-A levels in patients with high amounts of such CPPs, indicating that total CPP-bound fetuin-A and 'free' fetuin-A is usually measured in standard assay techniques. This group had previously reported experimental proof for their CPP concept in progressive vascular calcification in a rat model of severe CKD (adenine nephropathy). CPPs may conceptually work in a similar way to lipoproteins, that is, as 'mineral chaperones'. Preliminary data point to the possibility that the overall calcification inhibitory capacity of serum can be individually measured by a non-radioactive, nanoparticle-based assay in the future, and may thus serve as a novel biomarker in patients at risk. Oxygen is an essential molecule for life, and hypoxia induces damage in vital organs. In addition to causing uremic symptoms, uremic toxins may accelerate organ injury. We found that uremia produces oxidative stress, which leads to inefficient oxygen utilization by tubular cells. This results in increased oxygen consumption of the kidney and aggravates hypoxia. This mechanism may also serve to aggravate ischemic injury of vital organs such as heart and brain in uremic patients.
Furthermore, indoxyl sulfate, a representative uremic toxin, dysregulates an oxygen-sensing mechanism and suppresses erythropoietin production in the kidney. This possible connection between a uremic toxin and the desensitization of the oxygen-sensing mechanism in EPO-producing cells may partly explain inadequate EPO production in kidneys of patients with end stage kidney disease. Suppression of erythropoietin expression and subsequent development of renal anemia will aggravate hypoxia of organs in the body.
The hypoxia response is regulated primarily by hypoxia-inducible factor (HIF), influencing metabolism, cell survival, and angiogenesis to maintain biological homeostasis. Some of the histone demethylase enzymes, which have the Jumonji domain-containing family, are induced by hypoxia in an HIF-1-dependent manner. While hypoxia results in energy depletion, it also poses long-term consequences via epigenetic changes.
SY2-4
Protecting the Diabetic Organ Against Ischemia-Reperfusion Injury
Fredrik Palm
Division of Integrative Physiology, Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden Ischemia-reperfusion injury (IR) is a major cause of acute renal failure and can be a consequence of congestive heart failure, sepsis, volume depletion, renal artery stenosis or following shock from any cause. IR-induced acute renal failure affects 5-20% of patients admitted to the intensive care unit and brings in its trail up to 50% mortality. In addition, renal IR can be a major setback after kidney transplantation, contributing to kidney allograft dysfunction. Despite advances in treatment and research, these numbers have not improved over the past decades. Thus, treatment options to prevent or reverse IR remain a therapeutic challenge.
IR-induced injury is characterized by inflammation, fibrosis, tubular and tubulointerstitial damage, glomerulosclerosis and functional impairment such as decreased glomerular filtration rate. The injuries originate from the deficiency of oxygen, but paradoxically also from the restoration of blood flow and pre-renal, renal, as well as post-renal factors can contribute. Interestingly, both diabetic patients hypoxia, and most of them are mediated through a pair of transcription factors, hypoxia inducible factors-1α (HIF-1α) and HIF-2α. Macrophages, key mediators of inflammation, are activated and accumulate in hypoxic area. Macrophages are currently classified into M1 (pro-inflammatory) and M2 (anti-inflammatory). However, the molecular mechanisms of M1 and M2-specific activations remain elusive.
Here we revealed M1 and M2 specific functions of HIF-1α and HIF-2α, which play essential roles in the initiation and resolution of inflammation. HIF-1α was acutely induced in M1 activation, whereas HIF-2α was exclusively expressed in M2, but not in M1 macrophages. Th1 cytokines such as IFNγ induced HIF-1α, but strongly suppressed HIF-2α. In contrast, Th2 cytokine, including IL-4 increased HIF-2α level. We identified inducible NO synthase (iNOS, a M1 marker gene) as a HIF-1α target, and arginase1 (arg1, a M2 marker gene) as a HIF-2α target gene, respectively. These two enzymes compete for the common substrate, l-arginine, and inhibit each other's function. HIF-1α elicits NO production in M1, however, HIF-2α suppresses NO production through arginase1 induction in M2 macrophages. The balance between HIF-1α and HIF-2α determine that of iNOS/arg1, resulting in the regulation of NO production. To verify the roles of HIF-α in vivo, we generated macrophage specific HIF-1α knockout mice (mHIF-1α KO) and HIF-2α knockout (mHIF-2α KO). Intraperitoneal injection of lipopolysaccaride (LPS) induces plasma NO rises acutely (6hr), and it normalizes within 24 hours. In mHIF-1α KO mice, peak NO rise was attenuated. In contrast, mHIF-2α KO mice exhibited delayed recovery of NO level after LPS injection. Those results implied the essential role of HIF-1α in initiating NO production, whereas HIF-2α is critically important in the resolution.
Hypoxia also occurs in myocardial ischemia or cardiac hypertrophy, and is considered to accelerate the inflammatory processes in cardiac tissues.
However, the precise roles of hypoxic macrophage activation in cardiac hypertrophy or fibrosis are still unclear.
To analyze the roles of macrophage hypoxia signaling in cardiac remodeling, we performed transverse aortic constriction (TAC), a well-established experimental model for pressure overload-induced cardiac hypertrophy and fibrosis in mice. Using flow cytometric (FACS) analysis, we characterized the inflammatory cells that were recruited to the heart after TAC. We found that at 2 and 4 days after TAC, CD11b positive F4/80 mid macrophages accumulated in the heart. Using pimonidazole, a probe for hypoxia, we then analyzed for those cells that may have been distributed in hypoxic areas, and identified that M1 macrophages (CD11b positive, F4/80 mid, Ly6G negative, Ly6c positive) markedly accumulated in these areas. To verify the roles of hypoxia mediated activation of M1 macrophages in cardiac remodeling, we examined the effect of TAC-induced cardiac remodeling in mHIF-1α KO mice. While there were no significant differences in the degree of cardiac hypertrophy or systolic function between mHIF-1α KO and wild type mice, myocardial fibrosis was more pronounced in mHIF-1α KO mice. The number of α-SMApositive cells, a marker of myofibroblasts, was also significantly elevated in mHIF-1α KO mice, suggesting the activation of myofibroblasts. These results demonstrate the importance of M1 macrophage hypoxic response in the regulation of cardiac fibrosis, as well as suggesting macrophages may have novel interactions with cardiac fibroblasts during cardiac remodeling. Abstracts Decreased β cell mass as a result of increased apoptosis is an important property of type 2 diabetes. A physiological animal model of β cell apoptosis is crucial for understanding the pathophysiology of diabetes and for developing new strategies for preventing the progression of diabetes. We performed metabolic studies in wild-type and Gck +/-mice, fed either diet containing a combination of sucrose and oleic acid (SO) or isocaloric diet containing linoleic acid instead of oleic acid (SL). In Gck +/-mice, but not in wild-type mice, SL increased endoplasmic reticulum (ER) stress and apoptosis of β-cells, thereby leading to relative loss of β-cells, compared to SO.
Incretins are peptide hormones secreted after meal ingestion that potentiate glucose-stimulated insulin secretion. The two predominant incretins are glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP). Human recombinant GLP-1 has been shown not only to enhance glucose-stimulated insulin secretion, but also to increase islet cell proliferation and β-cell mass, and decrease cellular apoptosis in rodents. In addition, its effect of chronic administration upon β-cell growth and survival are thought to be mediated by Irs2. However, both GLP-1 and GIP are rapidly degraded and inactivated in vivo, primarily by the enzyme dipeptidyl peptidase-4 (DPP-4). Therefore, DPP-4 inhibitors to prolong the effects of endogenous incretins began to be developed as a novel strategy. Interestingly, a DPP-4 inhibitor protected against SL-diet-induced β cell ER stress and apoptosis in Gck +/-mice. Another DPP-4 inhibitor protected against high-fat diet-induced β cell apoptosis in Irs-2 -/-mice. These findings suggest that DPP-4 inhibitors may be extremely promising for the cure for diabetes.
Islet dysfunction is also seen in pancreatic α-cells. It has been shown that excessive glucagon secretion is present in type 2 diabetes. Such islet dysfunction interferes with blood glucose control, and the resulting glucose toxicity in turn leads to further islet dysfunction. To protect the irreplaceable islets of patients with type 2 diabetes, the biggest challenge is to stop this vicious circle.
Incretin-based therapies now provide a key to solve this problem. In Japan as well as other countries, the clinical use of a DPP-4 inhibitor has recently become possible. DPP-4 inhibitors stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent manner. Since treatment can be conducted without placing a further burden on the islets, DPP-4 inhibitors characteristically do not cause hypoglycemia or an increase in body weight. As mentioned above, much attention is also given to the fact that DPP-4 inhibitors have been confirmed to show a β-cell mass-increasing action in rodents.
Based on the above-mentioned evidence, several kinds of DPP-4 inhibitors have been approved in Japan and worldwide, and they revealed a strong blood glucose-lowering action in clinical practice. It is of course necessary to continue collecting data on its safety, but at present there have been no problematic events concerning its clinical use. It is not hard to imagine that the appearance of these DPP-4 inhibitors will cause a dramatic change in the treatment of type 2 diabetes. In view of the improvement in islet function, it may be recommended to use DPP-4 inhibitors from an early stage because there is neither concern regarding hypoglycemia nor an increase in body weight. DPP-4 inhibitors will not stop at being a simple blood glucose-lowering therapy, but with its hidden potential of actually leading to a cure for diabetes as such, it will definitely play a central role in the pharmacotherapy of type 2 diabetes in the near future.
and animals have increased susceptibility to IR injury. In diabetic rats, IR causes rapidly progressing kidney injury and kidney function four weeks after IR, kidney function in diabetic rats is only 1/5 compared to corresponding control kidneys. It has been proposed that the diabetes-induced intrarenal tissue hypoxia contributes to the increased susceptibility to the ischemic insult.
C-peptide is formed as a part of normal insulin synthesis, and cosecreted in equimolar amounts to insulin from the pancreatic islets of Langerhans. When insulin production is decreased, C-peptide production is affected to the same extent. C-peptide reduces diabetic complications in diabetic patients and in animal models of insulinopenic diabetes. We have previously shown that C-peptide decreases glomerular hyperfiltration, tubular sodium transport and inflammatory genes in the diabetic kidney, which may indicate a potential protective role against the increased susceptibility to IR injury in the diabetic kidney since each of these processes increase kidney oxygen usage. In addition, C-peptide has already been shown to protect against cardiac IR injury in vitro.
Our recent results clearly show that when administered at the time of the ischemic insult, C-peptide protects the diabetic kidney from IR damage. This is evident as markedly improved glomerular filtration, renal plasma flow and tubular function. However, only slight improvements in morphology were observed. It is therefore concluded that C-peptide protects the diabetic kidney against functional deteriorations rather than preventing the commonly IR-associated morphological changes. Since C-peptide inhibits the diabetes-induced excessive oxygen usage, partly by blocking active tubular sodium transport, it is likely that the protective mechanism involves restored intrarenal oxygen availability. Thus, C-peptide could provide a new therapeutics for protecting the already hypoxic diabetic kidney from IR damage.
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SS1-1
Overview: Recent Progress in Blood Glucose Control
Yasuo Terauchi
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
In the past, the treatment of type 2 diabetes was aimed at improving the two pathologic characteristics, namely islet dysfunction and insulin resistance. The results of UKPDS (United Kingdom Prospective Diabetes Study) showed that β-cell function has usually declined by 50% by the time a diagnosis is made, and that it continually declines over time. It seems that this decline in function may also be related to a decrease in the β-cell mass. Decreased proliferation and/or increased apoptosis can be involved in the pathogenesis of decreased β-cell mass. We previously demonstrated that glucokinase (Gck) and insulin receptor substrate (Irs)-2 are required for β-cell hyperplasia to occur in response to high-fat diet-induced insulin resistance. for diabetic patients undergoing HD. Here, we describe the clinical efficacy and safety of DPP-4 inhibitor for patients with CKD, including those receiving dialysis.
SS1-3
Abnormal Lipoprotein Metabolism in Diabetic Nephropathy
Tsutomu Hirano
Department of Internal Medicine, Division of Diabetes, Metabolism, and Endocrinology Showa University School of Medicine, Tokyo, Japan
It is well known patients with diabetes have a high incidence of cardiovascular disease (CVD), and the incidence of CVD becomes substantially elevated when diabetic nephropathy is developed. The pathogenesis of CVD in diabetes is multifactorial, but dyslipidemia is thought to be a powerful risk factor for CVD. Although lipid metabolism has been extensively investigated in diabetes, little information is available concerning the influence of nephropathy on diabetic dyslipidemia. The mechanisms for dyslipidemia in diabetic nephropathy are multifactrial and complex. Plasma lipid profile are largely changed in the stage of nephropathy. Diabetes per.se. is a basic component causing plasma lipid abnormalities. Long-term hyperglycemia causes generalized vascular endothelial damage, which reduces functional lipoprotein lipase, leading to increase TG and decrease HDL-cholesterol. In overt-diabetic nephropathy, hypoproteinemia markedly increases LDL-C, and renal failure specifically increases remnant lipoproteins and decreases HDL-C and LDL-C.
Plasma lipid profiles change substantially as the nephropathy advances. In the early stage of diabetic nephropathy, hypertriglyceridemia develops. In overt-diabetic nephropathy, nephrosis markedly increases LDL-C, and renal failure increases remnant lipoprotein and decreases HDL-C. Even though the fasting hypertriglyceridemic subjects were excluded, the diabetic nephropathy group exhibited a remarkable postprandial hypetriglyceridemia or hyper-apo B48, a marker of chylomicrons.
We studied a possible mechanism behind the hypertriglyceridemia in early diabetic nephropathy with microalbuminuria. Plasma von Willebrand factor is widely used as a surrogated marker for vascular endothelial damage. vWF was significantly elevated in microalbuminuric and macroproteinuric diabetes, whereas it remained normal in non-diabetic patients with primary kidney disease having massive proteinuria. These results suggest that albuminuria in diabetes implies not only kidney damage, but also widespread vascular damage. We found a meaningful inter-relationship between plasma TG, lipoprotein lipase in post-heparin plasma, and vWF. When we compared the microalbuminuric diabetics with their normoalbuminuric counterparts, the former had higher TG, lower heparin-releasable LPL, and higher vWF. Interestingly, heparin-releasable LPL was inversely correlated with vWF. The lower LPL was associated with higher TG and lower HDL-C. We speculated that the generalized endothelial damage increases vWF and this decreases the functional LPL mass anchored on the endothelium, thereby inducing hypertriglyceridemia and low HDL-C.
It is well known that LDL cholesterol is markedly increased in nephrotic syndrome. But the precise mechanisms behind this remain Numerous drugs with different mechanisms of action and different pharmacologic profiles are being used with the aim of improving glycemic control in patients with type 2 diabetes. Therapeutic options for patients with type 2 diabetes and chronic kidney disease (CKD) are limited because a reduced glomerular filtration rate results in the accumulation of certain drugs and/or their metabolites. Conventional oral hypoglycemic agents, such as sulfonylurea (SU), are not suitable due to the risk of prolonged hypoglycemia; furthermore, metformin is contraindicated for moderate to advanced CKD. Therefore, in order to achieve good glycemic control, insulin injection therapy remains the mainstay of treatment in diabetic patients with moderate to advanced CKD, particularly in those receiving dialysis therapy. However, some agents have been used even in patients with CKD. Repaglinide and mitiglinide are rapid-and short-acting insulinotropic SU receptor ligands. They are rarely accompanied by hypoglycemia, and are attractive therapeutic options even in the dialysis population. In addition, alpha-glucosidase inhibitors are rarely accompanied by hypoglycemia and are administered without dose adjustments in dialysis patients. However, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines recommended that alpha-glucosidase inhibitors should be avoided in patients with advanced stage CKD and on dialysis. Furthermore, mitiglinide is not currently used in the US. Thus, recommended oral antidiabetic agents differ between countries. Moreover, dipeptidyl peptidase-4 (DPP-4) inhibitors and incretin mimetics are new antihyperglycemic agents, which may be used more frequently in the future in patients with type 2 diabetes and CKD. The potent and selective DPP-4 inhibitor vildagliptin improves glycemic control in patients with type 2 diabetes through incretin hormone-mediated increases in both α-and β-cell responsiveness to glucose. We conducted a prospective, open-label, parallel group, controlled study of 51 patients with type 2 diabetic patients undergoing hemodialysis (HD) during the 24-week study period. Patients were assigned to two groups: the vildagliptin group (n = 30) and the control group (n = 21). Vildagliptin was administered at 50 mg/day for the first 8 weeks. Then doses were titrated by dose-doubling to a maximum of 100 mg/day if glycated hemoglobin (HbA1c) or glycated albumin (GA) target levels had not been reached. No vildagliptin was administered to the controls. The average final dose of vildagliptin was 80 ± 5 mg daily. After 24 weeks, vildagliptin had decreased average HbA1c levels from 6.7% baseline to 6.1%, average GA levels from 24.5% baseline to 20.5% and average postprandial glucose levels from 186 mg/dL baseline to 140 mg/dL (all p < 0.0001). In the control group, we observed no such changes. Vildagliptin efficacy did not differ according to age or body mass index, but the GA reduction was significantly greater in the anti-diabetic agents-naïve group. Furthermore, in patients with higher baseline GA levels, a higher vildagliptin dosage was required to produce a noticeable effect. No serious adverse effects such as hypoglycemia or liver impairment were observed in any patient. Vildagliptin was effective as a treatment Abstracts During the earliest days, a major part of the research of MIA syndrome was studying biomarker of inflammation and poor nutritional status (protein-energy wasting) in relation to the high morbidity and mortality in ESRD patients. On another front, searching of biomarkers was shifted to the specialized fields such as vascular dysfunction and regulation of feeding. Moreover, recent studies focused on proand anti-inflammatory axis and synergistic action between biomarkers of inflammation and nutritional status for morbidity and mortality. Research field was not only protein production, but also genotype abnormalities of the corresponding factors, including single-nucleotide polymorphisms in genes involved in inflammation and nutrition, and epigenetics and uremia related acquired genetic abnormalities.
Several factors have been identified as independent risk factors for a high morbidity and mortality in ESRD patients. However, one of the most discriminative finding in the accumulated evidences is a paradoxical association based on interaction of inflammation and an abnormal body composition; a high BMI with better survival and of a low BMI, especially when accompanied by inflammation, with worse survival is evident in ESRD patients. This unique phenomenon may be a key for severe complications in ESRD patients, in particular the chronic kidney disease-mineral and bone disorder and the hyporesponsiveness of erythropoiesis stimulating agents as well as for the MIA syndrome itself.
Symposium 3
SY3-1
The Vulnerable Man-Low Testosterone Links to Uremic Phenotype
Peter Stenvinkel
Department of Renal Medicine, Karolinska University Hospital at Huddinge, Karolinska Institutet, Stockholm, Sweden
Testosterone deficiency or hypogonadism is a common finding in males with chronic kidney disease (CKD), that may be a consequence of not only the failing kidney per se but also drugs commonly used by nephrologists. It could also be hypothesized that uremic bone disease and proteinuria may affect testosterone levels. Several recent studies have shown that low testosterone levels predict poor outcome and cardiovascular events in CKD and dialysis patients. There is currently low awareness of this condition among both patients and Nephrologists, and in many cases testosterone deficiency remains unscreened and untreated. This talk summarizes the understanding on the role of testosterone deficiency at the crossroad of cardio-metabolic complications of CKD patients. Pathways discussed include, among others, the plausible role of testosterone deficiency in the development of anemia and EPO hyporesponsiveness, bone disease, cardiovascular disease and mortality. Today testosterone can be effectively replaced to the normal physiological range through various routes of administration and replacement of hormones to normal physiological levels is routine in endocrinological practice. Current information indicates that we should make a case for consideration of screening poorly understood. We firstly demonstrated that intracellular apo B degradation was decreased in hepatic cells when the cells were cultured with lower concentrations of bovine serum albumin. Reduction in apo B degradation leads to increase apo B secretion into the medium. In contrast, apo B production was unchanged at different BSA concentrations. These results suggest that decreased intercellular degradation of apo B is a major cause of the overproduction of apo-Bcontaining lipoproteins in nephrotic syndrome.
Apo CIII is a key inhibitor of the lipolysis and particle uptake of TG-rich lipoproteins. We found that apo B48 increased as diabetic nephropathy progressed. The ratio of apo B48 to TG was also substantially increased in diabetic renal failure receiving hemodialysis (HD), suggesting specific increases of chylomicron remnants. VLDLapo CIII levels were significantly elevated in diabetic nephropathy. VLDL-apo CIII was also higher in non-diabetic HD patients. Increased apo CIII suppresses LPL activity, which leads to hypertriglyceridemia in advanced CKD. HTGL, a key enzyme for hydrolysis of IDL, is markedly decreased in advanced CKD. HTGL is equally decreased in diabetic and non-diabetic HD patients, which may explain substantial increase of remnant lipoproteins in HD patients, irrespective of the presence of diabetes.
Small dense LDL (sdLDL) is more atherogenic than large buoyant LDL. LDL size became smaller with advanced stage of diabetic nephropathy, whereas HD patients had fairly large LDL. It may be explained that decreased HTGL in HD patients impedes the lipolysis of LDL.
Symposium 3-Keynote Lecture 2
KL2
Tide of MIA Syndrome; Will It Change?
Hirokazu Honda
Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
The malnutrition, inflammation and atherosclerosis (MIA) syndrome is highly associated with morbidity and mortality in end-stage renal disease (ESRD), in particular in dialysis patients. The presence of MIA syndrome is an important part of the residual uremic syndrome, although it is in part caused by coexisting comorbidity. This concept is closely associated with inflammation with elevated levels of C-reactive protein and inflammatory cytokines that predict malnutrition, cardiovascular disease and increased mortality in these patients.
In 1995, Professor Bergstrom was the first to report that high C-reactive protein, reflecting inflammation, was associated with poor nutritional status and poor survival in HD patients. This observation provided the basis for the proposal of the MIA syndrome, which is associated with most premature deaths in ESRD patients. Four years after this first report, the MIA syndrome started to become an increasingly accepted term to describe the presence of poor nutritional status together with inflammation and cardiovascular disease/atherosclerosis in ESRD patients. glyceride (Rho = -0.19, P = 0.03). In a multivariate logistic regression model, both PTX3 and CRP levels were independently associated with nutritional risk defined by GNRI < 91.2. Although CRP levels had a negative association with albumin (Rho = -0.38, P < 0.0001) but not with BW/IBW, PTX3 had a negative association with BW/ IBW (Rho = -0.39, P < 0.0001), but not with albumin.
Conclusion: Both PTX3 and CRP predict nutritional risk in HD-patients. The association between CRP and nutritional risk calculated on the basis of GNRI depends on albumin levels, yet PTX3 had a strong association with anthropometric parameters. Further observational and mechanistic studies are warranted to characterize the role of PTX3, which may be a candidate for emerging inflammatory markers for the assessment of PEW because of the unique association with nutritional status in the dialysis population.
SY3-3
Twenty Years of Change in the Prevalence of Coronary Heart Disease at the Start of Renal Replacement Therapy: Insight into MIA Syndrome
Nobuhiko Joki, Yuri Tanaka, Hiroki Hase
Department of Nephrology, Toho University Ohashi Medical Center, Tokyo, Japan
Background: The present study analyzes the prevalence of coronary artery disease (CAD) in new patients on hemodialysis and trends in parameters of malnutrition and inflammation over the past two decades.
Design, Participants and Measurements: This single-center, longitudinal cross-sectional study examines data from 222 new consecutive patients without cardiac diseases who were on hemodialysis (age, 63 ± 12 years; male, 69%; diabetic nephropathy, 56%) between January 1993 and December 2010. All patients were routinely screened for CAD regardless of a suspicion of ischemic heart disease within three months of starting hemodialysis. We then equally assigned the 222 patients to seven groups based on the date of the initial dialysis session.
Results: The prevalence of CAD gradually decreased from 44% to 13% over 18 years (p = 0.01 for trend). The high density lipoprotein cholesterol (HDL-C) concentration increased over time (p = 0.002 for trend), whereas low density lipoprotein cholesterol (LDL-C) levels did not significantly change. Thus, the ratio of LDL-C/ HDL-C significantly decreased over that period (p = 0.005 for trend). The contributor to CAD over the past 20 years was analyzed using simple logistic regression analysis. Significant negative associations were found between CAD and each of BMI, EF, HDL-C, use of ESA, ARB/ACE-I and era. A history of smoking, the L/H ratio, and CRP level were positively associated with CAD. After adjusting by era, BMI and CRP, markers of malnutrition and inflammation were closely associated with CAD.
Conclusion: The prevalence of CAD has significantly decreased in patients with end-stage kidney disease over the last two decades. In spite of change in the medical management of CKD, malnutrition and inflammation might have played a critical role in this finding. and better management of hypogonadism in the male dialysis population. The renal community is in need of sustained evidence on the purported benefits of correction uremic hypogonadism.
SY3-2
The Novel Inflammatory Marker, Pentraxin-3, in HD Patients: Insights into Its Association with Nutritional Status
Tetsu Miyamoto
Second Department of Internal Medicine, University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan
Background: Persistent inflammation is a major driving force of the uremic phenotype, including protein energy wasting (PEW). Multiple pathways closely and causally interconnect the inflammation processes and PEW. Therefore, regular monitoring of inflammation biomarkers in dialysis patients may help clinicians to estimate patient nutritional risk. Furthermore, circulating inflammatory markers may have the potential to serve as primary targets for novel treatments such as nutritional or anti-wasting approaches. Despite these close relationships between inflammation and nutritional status, few studies have demonstrated an improvement in inflammatory status on the basis of C-reactive protein (CRP) following nutritional or anti-wasting intervention. Development of new inflammatory markers which are closely and specifically linked to nutritional status is thus needed in the dialysis population. Evaluation of inflammatory status using such biomarkers in combination with CRP could provide valuable information on PEW. Pentraxin 3 (PTX3) is a multifunctional soluble pattern recognition receptor which modulates the immunoinflammatory response and belongs to the same pentraxin superfamily of acutephase reactants as CRP. However, PTX3 and CRP may be involved in different pathophysiological mechanisms; hepatocytes are the main source of CRP, whereas PTX3 is produced at sites of inflammation by a wide range of cell types. Although CRP is directly associated with body fat, PTX3 levels have been reported to correlate negatively with anthropometric surrogates of fat tissue in two Swedish cohorts of ESRD patients. Additionally, an interventional study of healthy volunteers with a 2-week control of energy balance and physical activity showed that changes in fat mass and nutrient intake correlate directly with CRP, but negatively with changes in PTX3, suggesting opposite regulation of the two inflammatory markers in response to changes in energy balance. Against these backgrounds, we hypothesized that PTX3 is a specific inflammatory marker relating to PEW in dialysis patients.
Methods: Plasma PTX3 levels were cross-sectionally analyzed in relation to nutritional risk assessed by geriatric nutritional risk index (GNRI) in 184 Japanese prevalent HD patients. GNRI was calculated by the following formula: GNRI = [1.489×albumin (g/ dL)]+41.7×[body weight (BW)/ideal body weight (IBW)]; and BW or IBW was set to 1 when BW exceeded IBW.
Results: The median (10 th to 90 th percentile) level of plasma PTX3 (n = 184) was 4.0 (2.3-10.6) ng/mL. PTX3 levels correlated positively with the duration of dialysis (Rho = 0.36, P < 0.0001) and HDL-cholesterol (Rho = 0.24, P = 0.007), and negatively with BMI (Rho = -0.40, P < 0.0001), GNRI (Rho = -0.20, P = 0.008), and tri-Abstracts At the beginning of this century, neutral peritoneal dialysis (PD) solution with low/less glucose degradation endproducts (GDPs) was introduced in Japan. It has been penetrated as a standard solution in the clinical practice during last decade.
Because of the better biocompatibility of the neutral solution as compared to the conventional acidic one, the neutral solution has been expected to benefit patients in terms of the preservation of peritoneal function, the reducing risk of peritonitis, and the incidence of Encapsulating Peritoneal Sclerosis (EPS).
The NEXT-PD study was launched at 2008, in order to clarify the causes of PD drop-out and the incidence of EPS and its clinical background among patients using neutral solutions. 1,340 prevalent or incident PD patients were enrolled from 53 PD centers in Japan, and they were followed up until the end of March 2012. So far (as of March 2012), 734 patients (54.8%) reportedly stopped PD, or transferred to another modalities. Since studies on EPS occurrence reported elsewhere have been conducted among patients on the conventional acidic solutions, the NEXT-PD study would provide a novel finding on this critical issue. In the symposium, the latest data of NEXT-PD study will be presented, and report the incidence EPS development in new solution era.
SY3-4
Nadph Oxidase Induces Oxidative Stress in Patients with Blood Purification The chronic kidney disease (CKD) is known to a great risk factor for incidence of cardiovascular events. Various worsening factors such as hypertension, diabetes and aging accelerate CKD to end stage kidney disease (ESKD). The blood purification is then necessary for surviving the patients with CKD stage 5D, meaning ESKD. Some of ESKD patients show the malnutrition-inflammation-atherosclerosis (MIA) syndrome that is strongly associated with the poor outcome in ESKD. We previously reported that oxidative stress seemed to be increased according to CKD progression, and that oxidative stress evaluated oxidative LDL in serum was much higher in the patients receiving hemodialysis (HD) than it in serum of patients with peritoneal dialysis. Produced oxidative stress during HD session may be associated with MIA syndrome and postulate to induce vascular damages such as peripheral arterial disease (PAD) which is major complication of HD.
Hideyasu Kiyomoto
LDL-apheresis (LA) is recommended for some patients suffering PAD because the procedure ameliorates the peripheral circulation and rescues the leg necrosis. In our observation, some of PAD patients with HD exhibited dramatic improvement of severe symptoms such as skin ulcer after LA performance. Ischemic symptom due to PAD was also gradually improved in 65% of patients after LA. We confirmed that LA attenuated reactive oxygen species (ROS) in patients with ESKD having PAD symptom because membrane component of NADPH oxidase, p22phox gene expression was reduced in leukocyte of HD patients. ROS production was significant correlated with the inflammation status, while the patients having severe MIA syndrome were difficult to cure PAD.
In conclusion, advanced CKD patients, especially treated by HD, showed higher levels of oxidative stress via up-regulation of p22phox gene expression in leukocyte. Increased oxidative stress via NADPH oxidase may be a causative factor for MIA syndrome. 
History of Hemodiafiltration
Ingrid Ledebo
Gambro Research and Development, Lund, Sweden Hemodiafiltration (HDF) was created to combine the best of hemodialysis (HD) and hemofiltration (HF), i.e. superior removal of both small and large solutes. To provide conditions for both diffusion and convection, HDF requires dialysis fluid as well as sterile substitution solution.
The first clinical experience with HDF was made in Giessen, Germany in the late 1970s using AN69 membranes, Rhodial volume control devices, bedscales to control the weight loss and substitution solution in bags, 9 L/session. Considering the superior efficiency of HDF compared to standard HD, the therapy was initially applied with reduced treatment time, a strategy which later was abandoned.
The main limiting factor for any convective therapy is the need for large volumes of sterile fluid and this has shaped the evolution of HDF. Substitution fluid in bags is heavy to store and handle and it is expensive. Initially it contained lactate and when bicarbonate-containing fluid became available, the cost increased. On-line prepared substitution fluid, which was developed for HF, became generally available also for HDF in the mid-1990s. Having free access to highquality fluids of individualized composition -ultrapure dialysis fluid and sterile, non-pyrogenic substitution solution -opened up possibilities for optimal HDF therapy.
The limitations posed by the fluid availability have stimulated creativity and several technically sophisticated systems for HDF with automated fluid replacement by internal filtration of dialysis fluid have been devised. They are usually more cost-effective than on-line HDF, but less efficient and rely on fluid which cannot be referred to as sterile.
In the mid-1990s high-flux membranes and high flow rates increased the efficiency of HD, providing ß 2 -microglobulin clearance similar to classic HDF. However, with access to on-line prepared fluid the convective component of HDF was gradually increased. Today the goal of a HDF session is to provide at least 20L of effective convective clearance.
SS2-3
PD Catheters and Placement Techniques Towards Paramount Outcome
Minoru Kubota
Oji Hospital, Tokyo, Japan
The main role of the PD catheter is infusing and draining the dialysis solution with an appropriate flow rate without solution leakage as an access to the abdominal cavity, therefore catheter may be the life line for the PD patients. To accomplish better outcome of peritoneal dialysis, numbers of modifications have been applied to the original "Tenckhoff catheter", and to the catheter placement technique worldwide. Also in Japan, the effort to improve PD patients' outcome has being done, in the field of peritoneal access, the placement technique and treatment for catheter-related complications. In this seminar, originally developed catheters and techniques from our country will be presented.
We have two long models of catheter length in 65cm (CAVA CATH) and 80cm (ULLC), adjusted the length for the upper abdominal and presternal exit site, respectively. Both upper abdominal and presternal exit are gradually increasing in Japanese patients, because of their fewer risk for exit site infection when bathing. In addition, the ULLC catheter is long enough to make long subcutaneous tunnel for shoulder blade exit for the patient with dementia, which is originally developed from Oji hospital, Japan. Moreover, these long catheters have an advantage to surgical treatment for the intervention of tunnel infection, because of their long subcutaneous pathway.
As for the catheter placement technique, surgical insertion of the catheter is the most common method, in Japan. Some facilities use laparoscopy, for catheter insertion especially for the patients with prior abdominal surgery whose abdominal cavity is seemed to be adhesive. In 1993, Moncrief and Popovich developed their unique technique for catheter placement, in which after embedding the end of the catheter subcutaneously followed by catheter exteriolization when use. This technique is called "Stepwise initiation of PD using Moncrief and Popovich technique; SMAP" in Japan. The SMAP is now widely used in Japan, and almost 30% of the PD patients commence PD using this technique.
Despite several advantages compared to hemodialysis, only 3% of ESRD patients are using PD as renal replacement therapy in our country. A similar trend can also be seen in US and Europe. The causes of the underutilization of PD have been discussed in recent years. Among factors likely responsible for underutilization of PD, catheter insertion by the nephrologists may be considered one of the most important issues to improve PD underutilization. In 2008, we have organized the catheter insertion workshop for nephrologists. The workshop was held thrice annually, and more than 200 nephrologists participated the workshop. This catheter insertion workshop for nephrologists showed a definite effect on the PD program of the attendee's hospital. This challenging educational attempt will also be introduced in the seminar. Abstracts HDF, because these membranes possess performance that internal filtration is carried out automatically. So in spite of HD treatment, as a result, the effect that is equal to postdilution HDF treatment.
There are no studies about predilution on-line HDF corresponding to prognosis and cardiovascular events. And we must use a hemodiafilter during the on-line HDF treatment now. However, the hemodiafilter has not been reached the removal LWMPs which we demand. The most important points are multicenter randomized control prospective trial of predilution on-line HDF, we must carry out this study in a near future.
JSY-4
Clinical Benefits of Post-Dilution Online Haemdiafiltration
Sudhir K Bowry, Bernard Canaud
Fresenius Medical Care, Bad Homburg, Germany
Haemodiafiltration is characterised by the controlled replacement of ultrafiltered plasma water by infusion of substitution fluid into the blood of the patient. The addition of substitution fluid and its subsequent removal from diluted blood has been shown to be a more efficient means of reducing the levels of uremic toxin that accumulate in chronic kidney disease (CKD). As uremia is attributed to the build-up of a large number solutes of various sizes, there is widespread recognition today that both small and large uremic retention solutes, commonly referred to as uremic toxins, need to be removed during renal replacement therapy to enhance patient-well-being.
A number of treatment strategies have been developed to achieve this objective. A fundamental approach to enable the removal of larger uremic solutes is the application of high-flux dialysis membranes having sufficiently higher mean pore sizes to allow large solutes to pass through yet restrict the leakage of useful substances beyond a certain size range. By adding and removing substitution volume in conjunction with the use of high-flux membranes, a more efficient means of removing a broad spectrum of uremic toxins is achieved. This approach incorporates convective transport (passage of solutes following fluid flow by ultrafiltration across high permeability membranes, also known as 'solvent drag') component in addition to predominantly mechanism of diffusive transport (based on difference in concentration between the blood and dialysis fluid compartments) mechanism for the removal of solutes.
The two main clinical approaches of fluid substitution in OL-HDF are pre-and post-dilution HDF, of which the latter is the most common. Both techniques have their respective advantages and limitations and prescription is largely a clinical, patient-dependent choice. In this presentation the clinical evidence, particularly on patient survival, supporting post-dilution OL-HDF will be summarised especially in relation to the conclusion and findings of two recent large-scale clinical trials (the CONTRAST Study and the Turkish Online HDF Study). The emerging trend and importance of convective volumes and concept of "convective dose" will be presented in correlation with ß2-microglobulin that is both a recognised marker of middle molecules as well as being involved in associated with poor outcomes in a number of diseased states including CKD.
JSY-2
Inflammation in Chronic Kidney DiseaseThe Fire That Burns Within
Peter Stenvinkel
Inflammation is a major driving force of the uremic phenotype and single and longitudinal changes of C-reactive protein provide important outcome prediction. The uremic phenotype, which commonly includes both persistent inflammation and protein energy wasting, has recently been shown to overshadow the traditional risk profile. Accumulating data have indicated that the presence of persistent inflammation modifies the risk relationship of biomarkers via mechanisms related to self-enhancement of the inflammatory cascade and exacerbation of the uremic phenotypes. As several small randomized controlled trials have showed that various nutritional, nonspecific immunomodulatory and targeted anti-cytokine interventions may have anti-inflammatory potential, future randomized control trials are needed to explore whether interventions specifically targeting inflammation will improve the dismal prognosis in end-stage renal disease.
JSY-3
Clinical Benefits of Predilution on Line HDF
Kenji Tsuchida, Jun Minakuchi
Kawashima Hospital, Department of Kidney Disease (Dialysis and Transplantation), Tokushima, Japan
As you know, there are two types in HDF treatments, predilution and postdilution. In Japan, the on-line HDF treatment has used for renal replacement therapy (RRT) for 20 years ago among clinical doctors. However this treatment has not been popular because it has not been recognized RRT on Japanese government. Generally, postdilution HDF has advantages of the removal of low weight molecular proteins (LWMPs) and protein-binding uremic toxin than predilution HDF. So postdilution HDF has been widely used in the world, but in Japan, predilution on line-HDF has been popular treatment.
Why predilution HDF has been popular treatment in Japan? There are some reasons for it. In the removal of a part of LWMPs and protein-binding uremic toxin, for example p-cresol and homocysteine, predilution HDF is superior to postdilution HDF. In addition, there are several reports of the biocompatibilities in predilution HDF. Predilution has a merit of regression of shear stress, and the synthesis of cytokine and cellular adhesion molecules. Moreover, predilution HDF has merits of stability in blood pressure during treatment. In such situation, small clinical outcomes were reported, such as prevention of development of amyloidosis, anemia, osteoarthritis and pruritus in clinical efficiency of predilution HDF. In Japan, over 90% dialysis patients has been received hemodialysis (HD) therapy with the super high flux dialysis membrane. These super high flux dialysis membranes have abilities of over 50mL/min of beta-2 microglobulin clearance. And these membranes have the same power as postdilution The mechanism of this issue has not yet been clarified but some factors could explain the advantage such as well balanced solute removal pattern, reduction in the small nutrient loss and biocompatibility. Generally the efficacy of small solute and LMWP removal is better in post-dilution HDF than in pre-dilution; however, the more efficient removal is not always leads to the better improvement of patients' symptoms and feelings. This issue suggests us that the biocompatibility is an essential aspect for evaluating the quality of dialysis modality.
There are three possible mechanisms for the advantages of predilution online HDF in biocompatibility. First, large amount of filtrate inside the dialyzer could drain away chemical eluting substances from the dialysis membrane and some reactive proteins. Second, the dilution of the blood could reduce the chance of blood cells to close contact to the s dialysis membrane surface, and then it could reduce the sequential inflammatory response. Third, the blood dilution itself reduces the production of free radicals. We believe the biocompatibility of pre-dilution online HDF is closely related to the improvement of dialysis related various symptoms.
Free Communication 1 (Best Abstract Session)
O1-1
The Background: Synthetic polymers, such as polysulfone (PS) and polyethersulfone (PES), are widely used as dialyzer membrane materials. These synthetic polymers are hydrophobic in nature, and therefore water insoluble. Polyvinylpyrrolidone (PVP) is blended with these dialyzer membranes as an agent for making small pores. This increases the permeability and improves the biocompatibility of these membranes. Because the accumulation of PVP induces a granulomalike reaction in humans, special attention should be paid when using these membranes for patients on maintenance dialysis. We also investigated whether in-line steam sterilization reduces the substances eluted from these membranes.
Methods: Four types of dialyzer membranes, APS-15SA (Asahi Kasei Medical), CX-1.6U (Toray), PES-15Eαeco (Nipro), and FX 140 (Fresenius), were used. Substances eluted from the dialyzer membrane were quantified by measuring either the concentration of PVP or UV absorbance (wavelength 220 nm) at the time of 12 and 24
JSY-5
Technological Aspect of Pre or Post-Dilution On-Line HDF
Akihiro C, Yamashita
Shonan Institute of Technology, Fujisawa, Japan
Objectives: There are two major modalities for dilution in hemodiafiltration (HDF) therapy, i.e., pre-dilution and post-dilution. Most HDF treatments are performed in post-dilution mode, employing higher blood flow rates (Q B , 350-400 mL/min) in European countries, whereas pre-dilution is a predominant technique of dilution in Japanese HDF treatments under Q B of 200-250 mL/min. Then the specification required for diafilters may not be same in European and Japanese treatments. This paper discusses the objectives of HDF treatments and optimal design of diafilters for further success of HDF.
Current HDF Treatments in European Countries and in
Japan: The purpose of HDF treatment in European countries is to remove beta2-microglobulin (beta2-MG) and larger solutes without losing much albumin in order to reduce the risk of ESRD patients. Therefore, the membrane with low permeability for albumin is the main stream of the choice for diafilters. Since Q B of 400 mL/min is common, post-dilution would be the only realistic choice in order to avoid high pressures in blood. On the contrary, since the purpose of Japanese HDF is to remove solutes much greater than beta2-MG (up to alpha1-microglobulin, MW 33000) under Q B of 200-250 mL/min, rather sharp cut-off between these molecules and albumin is focused. One way is to overcome this problem is to employ pre-dilution online technique in order to control the amount of albumin loss more easily.
Design Concept of Novel Diafilters: In European postdilution HDF and in Japanese pre-dilution HDF, hollow fibers with a little larger diameter (as large as 300 μm) may be suited in order to avoid high pressures in blood because the inlet flow rate of blood to the diafilter is about 400-500 mL/min in both modalities. In overall, the internal filtration that is important to increase the rate of solute removal in HD is not necessary and may not be preferred because the forward ultrafiltration from blood compartment to the dialysis fluid compartment is not occurring in the portion where the reverse ultrafiltration, the opposite to the forward ultrafiltration, is occurring. Much larger membrane surface area (3.0 m 2 ) may be preferred for postdilution HDF with a little smaller pore diameter to limit the amount of albumin loss with a design of shorter effective length and larger diameter of the outer case.
Conclusions: The design concept of a diafilter is crucial to increase the performance of the device, exclusively used in on-line dilution treatment systems.
JSY-6
Biocompatibility of Pre-Dilution Online HDF
Ikuto Masakane
Yabuki Shima Clinic, Yamagata, Japan
In the previous papers we proposed that pre-dilution HDF has more beneficial effects on dialysis patients than post-dilution HDF. Abstracts
Results: From the spikes examination using a fluorescence standard particle, standard bacteria and dialysis fluid separation bacteria, this equipment was shown to have superior detection capability.
Moreover, it was confirmed that the contamination which may take place suddenly is fully detectable in real-time monitoring system connected with the dialysis equipment.
Conclusion: New bacterial real-time monitoring system was confirmed that it can detect early the amount of bacteria present in dialysis fluid with high accuracy and high precision without need of performing a sampling and pre-processing operation.
It seems that this equipment greatly contributes to the contamination management of the dialysis fluid. Background: We observed that the pulse oximeter showed the elevation in oxygen saturation (SO 2 ) in some patients during hemodyalysis (HD) treatment. One of mechanism is described that the buffer dialysate contribute to the diffusion of oxygen to the blood. The dialysate containing high partial pressure of oxygen (PO 2 ) content (high O 2 dialysate) is assumed to transfer more oxygen to the blood during HD treatment. This study examined the effects of the commercially available dialysate and high O 2 dialysate on the PO 2 in blood during the simulated circulation of HD.
O1-
Methods: APS-21E (Polysulfone membrane, Asahi Kasei, Tokyo, Japan) dialyzers were used in this study. Batches of 1000 ml of bovine blood of 30% of hematocrit (Ht) were prepared. We conducted HD at Q B = 200ml/min, Q D = 500ml/min for 120 min. KINDALY AF-2 (FUSO, Osaka, Japan) containing bicarbonate were used as dialysate. All the experiments were performed at 310K. Dialysate containing high PO 2 content was made by gas compressor to prove the increase up to 300 mmHg of PO 2 in dialysate after deaeration. Gas compressor was set up between reverse osmosis (RO) water line and the console. We conducted HD circulated with bovine blood in Ht of 30% using either usual dialysate or high PO 2 dialysate. Blood samples were collected from both inlet and outlet of dialyzer at 17 points during HD treatment. pH, PO 2 , PCO 2 , HCO 3 and O 2 saturation were determined by i-STAT (300F Abbot Point of Care Inc, USA).
Results: PO 2 showed in blood and usual dialysate were 35.0 mmHg and 145 mmHg, respectively before the circulation. PO 2 always revealed higher in outlet than in inlet of the dialyzer. PO 2 content increased for the first 105 min after starting the experiment and then reached a plateau at 110 to 115 mmHg in usual dialysate. PO 2 in the high oxygen dialysate showed a plateau among 240 to 300 mmHg after the increase for the first 30 min. These values were higher than usual dialysate. hours of indwelling after priming. Moreover, we evaluated the concentration of PVP or UV absorbance of the dialysate effluents after 4 hours of recirculation with 200 ml/min saline flow. We also examined the effects of in-line steam sterilization of FX 140.
Results: APS-15SA and CX-1.6U showed the highest UV absorbance values after 24 hours of indwelling (n.s.) and it was the lowest with FX 140 (n.s.) while PVP content was the highest with APS-15SA (n.s.) and the lowest with CX-1.6U (n.s.). In the 4-hour recirculation test, the amount of eluted substances from dialyzer was the smallest with FX 140 by the UV absorbance test among all the dialyzers studied (p < 0.05) and CX-1.6U was the lowest by PVP content (p < 0.05). After in-line steam sterilization with FX 140, both UV absorbance and PVP concentration were significantly reduced in the 4-hour recirculation test with saline (P < 0.001).
Conclusion: Overall, FX 140 showed the tendency of being low in the amount of eluted substances from the dialyzer. As the eluted amounts from FX 140 were significantly lowered in both UV absorbance and PVP content after the in-line steam sterilization, the above results could be attributed to this sterilization method.
O1-2
Development of Real-Time Monitoring System on Bacteria in Dialysis Fluid
Tomotaka Naramura Introduction: The contamination management in dialysis fluid is indispensable and early detection of impurities is very important. However, the conventional bacteria detection like the cultivating method, a result cannot be fed back immediately but the subject still remains in aspect of safety.
In an attempt to solve the problem, we examined bacteriadetecting methods independent of cultivating operation focusing on fluorescence staining, by making rapid and high accuracy detection. However, it has been difficult to monitor bacteria in real-time without removing pre-processing such as sampling or the dyeing method.
As a result, we developed a world's first real-time monitoring system on bacteria which does not need sampling and pre-treatment operation.
Objectives and Methods: In the new equipment, a sample liquid is poured to a flow cell, and is irradiated with 405nm laser light continuously. A particle in the liquid emits dispersion light, and further, when this particle is a viable particle, it emits fluorescence in the living body. Then, dispersion light and fluorescence are separated by the dichroic-mirror, and each number of particles is counted and displayed in real-time.
Using this equipment, fluorescence standard particles, the standard bacteria, and the separation bacteria from dialysis fluid were suspended in dialysis fluid, and the spike examination was conducted.
Further, real-time monitoring tests were performed by connecting with the dialysis equipment. Nagoya University Graduate School of Medicine, Nagoya, 2 Fujita Health University School of Medicine, Nagoya, 3 Meiyo Clinic, Nagoya, Japan Background: Hyperphosphatemia contributes to worsening vascular calcification and increased mortality in dialysis patients. To control serum phosphorus (P), dietary protein restrictions are routinely recommended to patients with hyperphosphatemia. Recently, it is advocated that inorganic additive P should be restricted because low dietary protein intake leads to protein energy wasting in dialysis patients. Here, we examined characteristics of patients who showed low estimated dietary protein intake and hyperphosphatemia.
Methods: We enrolled 81 Japanese dialysis patients (50 males, mean age 60 ± 11 years) who just started dialysis from June 2007 to March 2011 at two affiliated hospitals in Aichi prefecture, Japan. This study is a sub-analysis of the ongoing prospective Nagoya Immune System in ESRD (NISE) study. We examined serum P, normalized protein catabolic rate (nPCR) as a surrogate of dietary protein intake and geriatric nutritional risk index (GNRI) as a marker of nutrition at 1 year after initiation of dialysis therapy. We divided into four groups according to the median value of serum P and nPCR, Group A; P↑nPCR↓, Group B, P↑nPCR↑, Group C; P↓nPCR↓, GroupD; P↓nPCR↑.
Results: Serum P level had a significant correlation to higher nPCR. (R 2 = 0.27, P < .0001). The mean values of serum P and nPCR were 5.42 ± 1.4 mg/dL and 0.88 ± 0.16 g/kg/day, respectively. Group A was the youngest and Group D was the oldest of the mean age. Only 3% female belonged to Group A while 22% males did, and 25% females and 12% males belonged to Group D. nPCR was significantly lower in patients with diabetes (P = 0.0087). There was no difference in use of P binders, intact PTH levels, GNRI and incremental DW among these groups. Hematocrit was the lowest in Group C (P = 0.04) and total cholesterol level was the lowest in Group A and the highest in Group D (P = 0.03). The rate of cardiovascular (CVD) event during the observational period was the highest in Group A and the lowest in Group D (Group A; 41.7%, Group B; 13.8%, Group C; 25.9%, Group D; 0%, P = 0.015).
Conclusions: In early days of dialysis therapy, low dietary protein intake might not have a bad influence on nutrition. However, the patients who were suspected higher intake of additive P may be subject to CVD events. We suggest that education of quality of dietary protein and avoidance of harmful P might be required to inhibit excess calcification in Japanese dialysis patients. Muscle wasting in upper and lower limbs is very frequently observed in patients on chronic hemodialysis (HD). Recently, follistatin is shown experimentally to increase muscle mass and strength by direct antagonism of myostatin, a negative regulator of muscle growth (Muscle Nerve 2009). In addition, serum follistatin level increases following energy deprivation in healthy subjects (J Clin Endocrinol Metab 2011). So, we aimed this study to test whether serum folllistatin is associated with changes of muscle mass and strength in HD patients.
We measured total follistatin in 64 patients (age: 66 ± 10 years, HD vintage: 142 ± 122 months, male/female = 39/25), and compared those with mid-arm muscle circumference (MMC), percentile creatinine generation rate (%CGR) and handgrip power.
Serum follistatin was significantly increased in HD patients when compared with healthy subjects. Follistatin was correlated positively with serum interleukin-6 (r = 0.41, p < 0.01) while negatively with geriatric nutritional risk index (GNRI) (r = -0.31, p < 0.02). There was an inverse relationship between follistatin and MMC (r = -0.31, p < 0.02) and %CGR (r = -0.27, p < 0.05). In contrast, serum follistatin did not relate to handgrip power. There was also no relationship between serum follistatin and 25(OH)D levels.
These findings suggest that increased follistatin is related to inflammation and reduced muscle mass in HD patients, possibly indicating its counter-regulatory role for the processes of muscle wasting. Abstracts
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Bisphenol A in Chronic Kidney Diesease The estrogenic endocrine-disrupting substance bisphenol A (BPA) is extensively used as a starting material for many consumer plastic products including dialyzer materials. The present study was performed to explore plasma BPA levels in patients with impaired renal function and to investigate if dialyzers differing in elutable BPA influence plasma levels in patients on maintenance hemodialysis.
Methods: In vitro BPA was eluted from high-flux polyethersulfone (PUREMA H ® , referred as PUR-H), high-flux polysulfone (referred as HF-PS), and low-flux polysulfone (referred as LF-PS) dialyzers by recirculation with water for 180 min. In a cross-sectional clinical study, plasma BPA levels of outpatients with different stages of chronic kidney disease (CKD) from four different centers were determined. Furthermore, in a prospective, randomized, and crossover setting, 18 maintenance dialysis patients were subjected successively to four weeks of thrice weekly hemodialysis with each LF-PS, HF-PS and PUR-H. In addition, the fractions of protein-bound and free BPA were determined in a subset of dialysis patients.
Results: The mass of eluted BPA from the blood compartments varied considerably for the three dialyzers being very low for PUR-H (6.2 ± 2.5 ng; P < 0.001), intermediate for HF-PS (48.1 ± 7.7 ng) and highest for LF-PS (140.8 ± 38.7 ng; P < 0.01). In 152 prevalent patients with CKD enrolled in the cross-sectional trial, plasma BPA started to rise not before stage 3. Maintenance hemodialysis patients had more than six times higher BPA concentrations than patients with CKD stage 5 not yet on dialysis (10.0 ± 6.6 vs. 1.6 ± 1.8 ng/ml; P < 0.001). The BPA concentrations highly and inversely correlated with renal function. In the randomized, controlled study, the plasma BPA concentrations were highly elevated compared to healthy controls (range 9.1 ± 4.5 to 12.0 ± 6.0 ng/ml vs. ≤0.2 ± 0.1 ng/ml; P < 0.001) but no change of the levels was observed during hemodialysis with any of the three dialyzers in the course of a single treatment and over a period of four weeks. The protein-bound fraction of plasma BPA in the dialysis patients was 74 ± 5%.
Conclusions: Renal function and the total quantity of ingested BPA are essential parameters affecting plasma BPA concentrations. Dialyzers are one source of BPA but even large differences in the elu- Background and Objective: TLR2 and TLR4 expressions in CD16 positive cells were diminished in prevalent hemodialysis patients. However, impact of dialysate purity on the expressions of the TLRs is unclear. Thus, we assessed the association of dialysate purity with the cell surface expression of TLR2 and TLR4 in those patients.
Design, Setting, Participants and Measurements: We analyzed 36 patients on prevalent hemodialysis who treated by conventional dialysate (endotoxin level in dialysate 0.01EU/mL; n = 22), or ultrapure dialysate (endotoxin level in dialysate < 0.001EU/mL; n = 14). Values for blood endotoxin activity and TLR2 and TLR4 expressions in CD16 positive cells were compared between the groups by cross-sectional design. Endotoxin activity in blood was measured by a novel neutrophil chemiluminescent assay using antibody to lipid A that is a component common to endotoxins of gram-negative bacteria.
Results: Endotoxin activity was significantly decreased in ultrapure dialysate group (0.17 ± 0.11 vs. 0.40 ± 0.19) compared to conventional group. Expression levels of TLR2 (ratio of geometric mean fluorescence intensity to control) in ultrapure dialysate group were more diminished than in conventional group, whereas TLR4 expression levels were increased in ultrapure dialysate group. In total patients, endotoxin activity levels were positively correlated with TLR2 expression levels, however, TLR4 expression levels were inversely associated with endotoxin activity levels. Design, Setting, Participants and Measurements: Nintyfive patients on prevalent HD who received the ESAs epoetin-β (n = 22), darbepoetin-α (n = 60) or neither (Control; no ESA, n = 13) were recruited to the study. CD34 + , cell count and levels of hs-CRP, IL-6, VEGF and ICAM-1 and carotid intima-media thickness (CIMT) were assessed at baseline. The numbers of CD34 + /erythropoietin receptor (EPOR) + , cells were determined in 35 and 8 patients in the darbepoetin-α and control groups, respectively. CD34 + , cells were counted after 6 and 12 months of darbepoetin-a treatment (n = 35). All patients were followed up for a mean of 28 months.
Results: Hemoglobin levels were lower, CIMT was more pronounced and the ESA dose was higher in patients with a low CD34 + , cells. High-dose darbepoetin-α therapy was an independent predictor of composite CVD events. However, this association disappeared when adjusted for the CD34 + , cell count with other confounders. Conclusions: High-dose ESA therapy seems to associate with a low CD34 + , cell count and be a risk factor for CVD events in prevalent HD patients.
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Searching Introduction: Placental growth factor (PlGF), pregnancy-associated plasma protein-A (PAPP-A), soluble receptor for advanced glycation end products (sRAGE) calcium binding protein S100A12 (EN-RAGE) and high mobility group box 1 (HMGB1) have been implicated as novel biomarkers in clinical research. It is becoming clear that testing various groups of patients in conjunction with various biomarkers may better the definition of inflammatory risk profile in patients with reduced renal function.
Subjects and Methods: The studied groups were as follows: 40 patients with AKI at the inception of renal replacement therapy, 42 patients starting dialysis defined as CKD 5, 31 long-term haemodialysis patients (HD) and 39 age-matched healthy controls. PlGF, sRAGE, EN-RAGE and HMGB1 levels were assessed using enzyme linked immunosorbent assay, PAPP-A levels using time-resolved amplified cryptate emission, and routine biochemical parameters were measured using standard methods.
Results: PAPP-A was elevated (P < 0.001) in AKI (20.6 ± 16.8 mIU/L), CKD 5 (27.8 ± 39.3) and HD (20.8 ± 9.9) compared with controls (9.1 ± 2.3); PlGF was elevated only (P < 0.05) in HD (11.5 ± 3.3 pg/mL) versus controls (8.5 ± 2.4). sRAGE was increased (P < 0.001) in CKD 5 (3227 ± 1458 pg/mL) and HD (2746 ± 1218) versus controls (1765 ± 721). EN-RAGE was (P < 0.001) elevated in AKI (492.4 ± 449.5 ng/mL) compared with controls (60.1 ± 61.8). Similarly, HMGB1 was (P < 0.001) elevated in AKI (5.88 ± 7.59 ng/ mL) versus controls (1.78 ± 1.25). Biomarkers significantly related to inflammatory parameters were EN-RAGE and HMGB1.
Conclusion: PAPP-A was significantly elevated in all studied groups. PlGF was elevated only in HD group. sRAGE was increased in CKD5 and HD groups. EN-RAGE and HMGB1 were significantly increased in AKI group. Multiple screening revealed that selected biomarkers, specifically EN-RAGE and HMGB1, showed a significant correlation with inflammatory burden in patients with reduced renal function.
Support: The study was supported by the research project of Charles University P25/LF/1/2 and by grant SVV 2012-264511. Abstracts Fibroblast growth factor 23 (FGF23) plays a crucial role in phosphate metabolism in chronic kidney disease (CKD). Oral phosphate loading and calcitriol stimulate FGF23 secretion although precise mechanisms underlying the stimulation of FGF23 remain to be studied. We compared the effect of oral phosphate loading with that of intravenous loading on FGF23 levels in normal and 5/6 th nephrectomized uremic rats.
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Intravenous Phosphate Loading Increases Fibroblast Growth Factor 23 in Uremic Rats
Uremic rats (Nx) and sham-operated rats (Sham) were fed a 0.5% phosphate diet for 2 weeks and then divided by 3 groups, 1) with the same 0.5% phosphate diet (NP), 2) with a high phosphate (0.8%) diet (HP), and 3) the NP rats with intravenous phosphate infusion (2M of solution, 20μl/hr) using a micro infusion pump (IV). Blood and urine were obtained 1 day (acute phase) and 7 days (chronic phase) after the interventions.
Both in acute and chronic phases, serum phosphate levels and fractional excretion of phosphate (FEP) were comparable between HP and IV in both Sham and Nx rats, respectively. Serum phosphate levels in both HP and IV were significantly higher than those in NP only in chronic phase of Sham and Nx rats, respectively. FEP in both HP and IV were significantly higher than that in NP in acute and chronic phase of Sham and Nx rats, respectively. In acute phase of Sham and Nx rats, FGF23 levels were comparable among 3 groups (NP, HP, and IV) while in case of chronic phase FGF23 levels in HP were significantly higher than those in NP, and this increase was further pronounced in IV only in Nx rats.
These results show that chronic intravenous phosphate loading increases FGF23 indicating alternative sensing mechanisms for FGF23 other than dietary route (gut) may exist in CKD. The number of patients with peripheral arterial disease (PAD) has recently increased, in especially hemodialysis (HD) patients. Low density lipoprotein apheresis (LDL-A) has been reported to be effective against PAD through a reduction in coagulation factors. Furthermore, we reported that LDL-A has vasodilatory effects by an increase in vascular endothelial growth factor production and anti-inflammatory effects by reduction of P-selectin and CRP (Clin Exp Nephrol 12: 9-15, 2008) . Peripheral blood stem cell transplantation has been recently reported to be effective against PAD, in which endothelial progenitor cells (EPCs) are mobilized in ischemic limbs. We assessed whether or not LDL-A could increase CD34(+) peripheral blood stem cells (PBSCs) defined as EPCs in patients with PAD.
O2-
Methods: We investigated 7 patients with PAD. Mean age was 68.4 ± 4.2 years old (mean ± SD). All patients had diabetes mellitus and renal failure. Hemoglobin A1c level was 5.8 ± 0.4% (mean ± SD). Six patients underwent hemodialysis (HD) and one patients who did not undergo HD showed elevated serum creatinine level (5.4mg/ dl). All patients were classified as stage IV in Fontaine classification and as group V in Rutherford classification. LDL-A was performed using a dextran sulfate cellulose column (Liposorber LA-15, Kaneka) after separation of plasma. LDL-A was repeated 4-10 times. Blood samples were drawn before and after the first session of LDL-A. PBSCs assessed as CD34(+) cells co-expressing CD45 weakly positive by flow cytometry.
Results: Out of 7 patients with leg ulcer, 4 patients showed improvement in more than 50% reduction of ulcer size by LDL-A. CD34(+) PBSCs measured by flow cytometric techniques increased significantly by one session of LDL-A treatment from 0.35 ± 0.21/ml to 0.54 ± 0.31/ml (mean ± SD, p = 0.025).
Conclusions: LDL-A increases circulating CD34(+) PBSCs counts and 4 of 7 cases improved wound repair, which might partly contribute to ongoing vascular repair. Background: Serious accidents occur from the dislodgement of needles during renal replacement therapy (RRT). This study aimed to investigate the effectiveness of body movement detection sensors in preventing such accidents.
Methods: Ninety adult patients undergoing RRT participated in this investigation. The body movement detection sensors comprised built-in ball sensors were mounted on the following joints: wrist, elbow, and shoulder. The patients' postural changes were investigated to categorize each patient's movement into high-and low-risk groups. For five patients who were categorized into these risk groups, the detection frequency of each sensor was recorded with patients' movements, and the effectiveness of each sensor was examined.
Results: Low-and high-risk movements were performed by 88%-92% and 8%-12% of patients, respectively. The detection rate of dangerous movements was 10.1% at the shoulder joint, 73.4% at the wrist joint, and 70.8% at the elbow joint. As the detection rate in the same timing of two sensors, the detection rate of dangerous movements was 97.8% at the wrist and elbow joints.
Discussion: The detection rate of dangerous movements was the lowest at the shoulder joint. This is because the shoulder joint sensor did not detect movements at the elbow or wrist joints. The detection rate of dangerous movements was the highest at the wrist joint. However, the detection rate of safe movements was high, thereby generating false-positive results. The detection rate of dangerous and safe movements was better using the elbow joint sensor compared with that using the other sensors. The detection accuracy of dangerous movements increased when the sensors at the wrist and elbow joints simultaneously detected a movement. Therefore, more effective detection was achieved using the advantage of these sensors.
Conclusions: The sensors differ in the frequency at which a movement is detected, depending on the joint at which they were mounted. These sensors seemed effective when two or more of them were utilized simultaneously. We developed a system to calculate Kt/V every minute from the start to end of hemodialysis and display the results on the dialysis monitor screen before the start of the dialysis. In this system, whenever the blood flow rate, dialysate flow rate, and/or water removal rate are changed during hemodialysis session, the Kt/V values after that point, including the Kt/V value at the end of dialysis, are recalculated, and the recalculated values are displayed in place of the previously calculated Kt/V on the monitor screen. With this system, therefore, it is possible to perform hemodialysis with the target Kt/V value by changing the hemodialysis conditions in a trial and error manner during hemodialysis until the recalculated postdialysis Kt/V value agrees with the target value.
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In this system, on the day of regular blood sampling, the total body fluid volume is calculated by urea kinetic modeling based on the actually measured pre-and post-dialysis serum urea levels. Then, for one month beginning the day of blood sampling, Kt/V is calculated during each hemodialysis session by analyzing the same urea kinetic model based on the previously determined total body fluid volume and dialyzer urea clearance calculated from blood flow rate, dialysate flow rate, KoA and water removal rate.
In 36 hemodialysis patients, a close linear correlation was found between the Kt/V values at the end of dialysis calculated by the system (y) and those determined on the basis of the actually measured pre-and post-dialysis serum urea levels (x) y = 1.0634x-0.0786, r = 0.998. Moreover, there was no significant difference between the Kt/V values calculated by the system (1.41 ± 0.18) and those determined on the basis of the actually measured pre-and post-dialysis serum urea levels (1.40 ± 0.16). These findings indicate that Kt/V values calculated by the system agree with Kt/V values obtained from actual measurements of serum urea levels. Abstracts
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Factors Associated with Premature Circuit Clotting in Continuous Venovenous Hemofiltration
Pongsathorn Gojaseni, Kamoldech Wongpornpakdee, Pattamaporn Kamjai, Thaweepong Pajareya, Anutra Chittinandana Division of Nephrology, Department of Medicine, Bhumibol Adulyadej Hospital, Bangkok, Thailand Background: Premature circuit clotting is one of the major problems in continuous renal replacement therapy (CRRT) leading to blood loss and decreased efficacy of solute clearance. The aim of this study, therefore, was to determine the factors associated with circuit life span in critically ill patients with CRRT.
Methods: A prospective observational study was performed in critically ill patients treated with continuous venovenous hemofiltration (CVVH) between July and December 2011. Patient clinical data and characteristics of CVVH prescription were analyzed to determine their influence on circuit life.
Results: A total of 40 patients (24 males, 16 females), aged 63.4 ± 17.6 years were included in this study. The mean filter life was 30.3 ± 20.8 hours and the total CVVH time was 68.0 ± 50.1 hours. Patients with premature circuit clotting (defined by circuit life span less than 12 hours) appeared to have lower age (51.1 vs 67.0 yrs, p = 0.015), higher plasma calcium (8.2 vs 7.4 mg/dL, p = 0.048) and lower plasma potassium (3.8 vs 4.7 mmol/L, p = 0.032). Filter life was not significant difference according to difference CVVH prescription and types of anticoagulation (including citrate). Lower dose CVVH ( < 25 ml/kg/hr) seem to have longer circuit life compared with higher dose group but this different was not statistically significant (37.93 vs 25.13 hrs, p = 0.139). Interestingly, 30 days patient survival rate in the group with premature circuit clotting was lower than the group with longer circuit life (0% vs 25.8%, p = 0.015).
Conclusion: Premature clotting of CVVH circuit was associated with poor patient outcome. Circuit life span may be increased by using lower CVVH dose. Okayama University of Science, Okayama, Japan, 2 Chiba Institute of Science, Choshi, Japan, 3 NagakeClinic, Okayama, Japan, 4 KawaiClinic, Japan
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Evaluation of the Mass Reduction Ratio of Urea Estimated from the Integrated Value of Urea Concentrations in Spent Dialysate
Objectives: The urea reduction ratio URR, have become clinical standards by which dialysis dose is judged in the United States. The URR is defined as the percent reduction in blood urea nitrogen concentration, during a single dialysis treatment. The actual post-dialysis BUN concentration, however, is not proportional to the amount of urea in patient's body because of the remove of fluid during dialysis, urea generation and non-uniform urea distribution in the body. In view of material balance, we estimated accurate mass reduction ratio or urea, m URR by means of in situ measurements of urea during hemodialysis treatment, and compered it with conventional URR.
Method: We used a chemiluminescence based urea sensor reported on 26 Then, the similar measurements were conducted in vivo during hemodialysis treatment of patients. Finally, the measured values of, m URR were compared with the theoretically calculated values of conventional URR based on the single-pool model using the value of the clearance of the dialyzer.
Results: In the case of the in vitro measurements, the values of the theoretical URR were well coincide with the values of, m URR measured and estimated at various flow rates of blood Q B . On the other hand, the values of the conventional URR were deviated more than 20% from the measured values of, m URR in some cases of in vivo measurements depending on the condition of the patients. Background: Hemodialysis procedure induced an inflammatory response. Acetate is directly and indirectly involved in generating several side effects such as hypoxia, vasodilatation, and the increased production of inflammatory cytokines. In Japan, 5 years ago, acetatefree commercial dialysate containing with 2 mEq/L of citrate (AFBD) was approved. Plasma pentraxin-3 (PTX3) is a new candidate marker for inflammation. PTX3 is rapidly produced and released by several cell types in response to primary inflammatory signals.
Methods: 32 clinically stable patients (Male;22,Female;10, mean age;56.2 ± 13.1y/o) on regular dialysis treatment, 3 times a week, 4-hr per session were selected for the study. All subjects were prospectively approached and gave informed consent to the study. They were switched to 3-weeks period of acetate (8mEq/L) containing bicarbonate dialysate (ACBD) therapy, after 3-weeks period of AFBD therapy, using the same water treatment system (RO+EDI;reverse osmosis and electrodeionization) for the ultrapure dialysis fluid and same dialyser. Neither bacteria nor endotoxin (ET) were detected in the dialysis fluid (bacteria < 0.1CFU/mL, ET < 0.001EU/mL). We evaluate blood pH, HCO3, citric acid concentration, high sensitive C-reactive protein (HS-CRP) and PTX3 levels before and after dialysis at the final session of both ACBD-and AFBD-period. PTX3 was measured using an ELISA kit. Plasma PTX3 concentrations after dialysis sessions were corrected for ultrafiltration-induced hemoconcentration. Statistical analysis was performed using student's t-test. Statistical significance was set at the level of P < 0.05.
Results: The mean plasma PTX3 levels were significantly increased after dialysis session (AFBD;6.71 ± 4.20ng/mL, ACBD;7.28 ± 3.63ng/mL) compared to before dialysis session (AFBD;4.86 ± 3.18ng/mL, ACBD;4.99 ± 2.87ng/mL) in both ACBDand AFBD-period. The mean change ratio of PTX3 on ACBD and AFBD were 158 ± 43% vs 145 ± 33%, respectively. There was the significant difference. The mean change ratio of HS-CRP on ACBD and AFBD were 112 ± 27% vs 104 ± 19%, respectively. There was no significant difference. The mean citric acid concentration was significantly increased after dialysis session compared to before dialysis session in AFBD. In ACBD, citric acid concentration did not change. These results suggest that PTX3 increases in plasma more rapidly than HS-CRP in response to a stimulus on dialysis procedure.
Conclusion: It is concluded that the absence of acetate loading in AFBD can lead to better biocompatibility for intradialytic inflammatory response. Objective: Establishment of blood purification centers in Cambodia and completion of the preparation for starting CAPD.
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Method: Between January and February 2010, dialysis facilities in Kanagawa and Osaka, to which members of NGO Ubiquitous Blood Purification International (UBPI) belong, accepted a total of five staff members (two physicians and three nurses) from Sen Sok International University Hospital (SSIUH) in Phnom Penh, Cambodia, and began a training program towards the establishment of blood purification centers in Cambodia. Between March and April, physicians, technicians, and nurses from Japan established a blood purification center in SSIUH in Phnom Penh with the above-mentioned five staff members. Hemodialysis was conducted in a patient for the first time on the 8 th of March, and in another three patients over the following three weeks. After making sure that dialysis had been conducted effectively, on the 24 th of March, Dr. Toru Hyodo, and Dr. Fumitaka Nakajima (representative of UBPI), Dr. Le Su Quoc (Baxter in Asia Pacific), and Dr. Sabo Ojano (president of SSIU) had a meeting, and determined the path to introduce CAPD in Cambodia in the future.
Result: They concluded a settlement regarding the following: 1) The purchase price of CAPD equipment will be the same as in Vietnam, 2) Staff in Cambodia will receive educational support from PD nurses and surgeons from Ho Chi Minh City, Vietnam, under the support of Baxter until PD can be introduced effectively without such support, and 3) Baxter will continue supporting SSIUH staff and providing them with information regarding PD. But CAPD has not been started until present of 2012 in Cambodia. The reason is that CAPD is still more expensive than HD twice a week.
Conclusion: Consequently, the preparation for starting CAPD was completed in Cambodia but has not been spread due to the cost. Abstracts deficiency. Although kinetics of carnitine within the body during hemodialysis has been investigated, the actual amount of carnitine eliminated into dialysate is unclear especially under modern dialysis technique. We measured the amount of eliminated carnitine with use of continuous syringe extract method (CSEM) during hemodialysis.
Methods: Chronic hemodialysis patients who were admitted to our hospital in order to seek the treatment of comorbidities were included. They were treated with hemodialysis of 4 hour session with high performance dialyzer. Carnitine was measured within both serum and dialysate. CSEM was used to collect a portion of dialysate at the outlet of dialyzer. We calculated total amount of carnitine loss into dialysate, as well as the clearance in the middle of sessions. The entire protocol had been approved by the ethical committee of our facility (approval number #3658).
Results: We included 10 patients into the present study. Their ages were 65.5 ± 6.1 years. Three patients were male. Two patients were diabetic. Dialysis vintages were 13.4 ± 10.1 years. Predialytic carnitine concentration was 47.5 ± 11.4 μmol/l. Carnitine clearance at the middle of the session was 103 ± 16 ml/min (blood side), 111 ± 25 ml/min (dialysate side), respectively; where plasma flow rate within dialyzer was 145 ± 23 ml/min. Total amount of carnitine eliminated into dialysate was 101 ± 21 mg/session.
Discussion and Conclusion: We determined the actual amount of carnitine eliminated into dialysate during hemodialysis session, which is less than the dose usually prescribed for supplementation of carnitine. Dialysis patients are known to be deficient of carnitine especially with longer vintage. Therefore, larger dose might be required to replenish the pre-existing deficit. However, the knowledge about the exact loss during dialysis sessions will lead to more appropriate dose of supplementation. Moreover, the discrepancy, if any, between actual loss into dialysate and oral intake or production within the body of carnitine might shed light onto the potential unknown mechanisms of carnitine deficiency in dialysis patients other than elimination during dialysis.
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How to Lower the Wet Weight and the Blood Test Values Before Dialysis Allowing Patients to Eat and Drink Freely
Yasushi Kunou
Nagoya City West Medical Center, Nagoya, Japan Definitions: 1) Wet weight is the weight before the first dialysis of the week. 2) Wet values are the blood test values before the first dialysis of the week.
Purpose: Dialysis patients often die before the first dialysis of the week, because they have most water and most uremic toxins in their body then. I show how to lower their wet weight and wet values.
Patients: All 58 dialysis patients at our hospital from July, 2011 through May, 2012 were studied.
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Water Soluble Vitamin E (TMG) Prevents GDPs Induced Peritoneal Damage Oita University Hospital, Department of Nephrology, Oita, 2 Oita University, Department of Internal Medicine 2, Oita, Japan Encapsulated peritoneal sclerosis or deterioration of peritoneal function is obstacle to the spread of Peritoneal Dialysis (PD).
One of important causes of deterioration of peritoneal membrane is thought to be several unphysiologic factors in peritoneal dialysis fluids (PDF).
To prevent the deterioration of peritoneal membrane due to these unphysiologic factors, addition of the substance with protection ability in PDF has been attempted.
Water soluble vitamin E (Tocopherol monoglucoside:TMG) has water solubility (100g in 100ml water).
First, we investigated the cytoprotective effect of TMG against the 3,4-dideoxyglucosone-3-ene (3,4-DGE)using human peritoneal mesothelial cells (HPMC).
Cell viability of HPMC was determined by MTT assay. Then, whether mouse peritoneal tissue damages induced by intraperitoneal administration of Methylgyoxsal, or glyoxsal (glucose degradation products :GDPs) solutions is ameliorated by TMG was examined.
In the examination of cell viability, 3,4-DGE decreased the cell viability of HPMC. However, the addition of TMG to 3,4-DGE markedly ameliorated decreasing of cell viability,
The peritoneum of GDPs-treated mice was significantly thickened compared with that of physiologic saline-treated mice. TMG prevented the thickening of mice peritoneum induced by GDPs and ameliorated accumulation of AGE and vascular endothelial growth factor, and type 1 collagen and a number of blood vessels.
In conclusion, TMG has cytoprotective effects of HPMC against 3,4-DGE. TMG also prevented peritoneal thickening; accumulation of AGE, vascular endothelial growth factor, and type 1 collagen; and neoangiogenesis in mice peritoneum induced by GDPs.
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Quantification of Carnitine Loss During Hemodialysis Session? Interim Results Background: Low albumin level is a strong predictor of mortality and morbidity among hemodialysis (HD) patients, yet few interventions are available to improve albumin levels. Thus, diagnosis of and intervention for hypoalbuminemia is important in the clinical management of HD patients.
Methods: The studies were conducted to investigate effects of oral nutritional supplementation on albumin metabolism.16 HD patients (7; male, 9; female) with hypoalbuminea (serum albumin Ϲ3.5g/dl) were enrolled. For the studies, The enriched BCAA complex (APQ10 ® , Nipro corporation Osaka Japan) was used. APQ10 ® , consists of 5 single amino acids (leucine,742mg; isoleucine,384mg; valine,497mg; glutamine,442mg; arginine,412 mg) , whey peptide, 601.5 mg (total protein 3100mg), antioxidants (coenzymeQ10, 15mg; ascorbic acid,30mg; alpha-tocopherol; 0.02mg), vitamin B1,0.8mg; vitamin B2,0.9mg; vitamin B6,2.5mg; vitamin B12, 1.5μg; niacin,6mg; calcium pantothenate, 2.3mg; folic acid 300μg. APQ10 ® , was administrated 3times daily (total protein 9300mg) for 6 months. To evaluate the effectiveness of oral supplementation with APQ10 ® , we measured serum albumin, body mass index (BMI), normalized protein catabolic rate (nPCR), percent creatinine generation rate (%CGR), total cholesterol (T-cho) and triglyceride TG). We also compared the ratio of oxidized (HNA; human nonmercaptalbumin) and reduced form (HMA; human mercaptalbumin) of serum albumin before and 3months after administration of APQ10 ® .
Results: Serum albumin levels was significantly increased (3.4 to 3.7 mg/dl) throughout APQ10 ® , administration period (p = 0.01). Significant correlation was found between serum albumin and nPCR (p = 0.01). Besides, increasing tendency was observed in %CGR while serum albumin level was increasing. However, there was no relationship between change in serum albumin level and other nutritional parameters such as BMI, TG and T-cho. In addition to these results, there was tendency to the percentage of HNA in patients who had serum albumin increase by APQ10 ® , administration. In particular, the patient who had 0.3g/dl increase of albumin level had more than 10% increase of HMA. On the other hand, no tendency to the ratio of HNA to HMA was observed in patients who had no increase in serum albumin level.
Conclusion: Oral supplementation with APQ10 ® , should increase serum albumin level effectively. In addition, APQ10 ® , may improve the ratio of HNA to HMA by accelerating albumin synthesis.
Methods: 1) They were allowed to eat and drink freely. 2) They received 7 hour long online HDF with a blood flow of 600 ml/min, a dilution flow of 6-24 L/h, a dialysate flow of 700 ml/min and 2.5 square meter surface area dialyzers three times a week. 3) We used a low sodium dialysate (136 mEq/L). 4) All diabetic patients who needed insulin received intensive insulin therapy.
Results: Their mean weight gain was 4.8% of their body weight before the first dialysis of the week.
Discussion on Why They Gained Little Weight: 1) If their blood glucose is 400 mg/dl, they feel thirsty and drink. If it is 80 mg/ dl, they do not drink. 2) Similarly, if their BUN is 150 mg/dl, they drink. On the long HDF with a high blood flow, their pre-dialysis BUN is close to 20 mg/dl. So they do not drink. 3) I show a peculiar case. Suppose patients receive short dialysis and do not drink at all. Then their pre-dialysis BUN becomes high. To lower it, water is absorbed from their stool. So they gain fluid weight even if they do not drink.
Conclusions: No matter how much water we remove during dialysis, it is meaningless if patients drink a lot. If we lower their wet values, they do not drink and their wet weight decreases. Thus we can decrease deaths before dialysis. Lowering wet values is important.
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My Reasoning as to Why Patients on 8 Hour Long Online HDF with a Blood Flow of 600 ml/min Do Not Have Hypertension
Yasushi Kunou
Nagoya City West Medical Center, Nagoya, Japan
Purpose: I will explain why patients on long HDF with a high blood flow do not have hypertension.
The First Reason: Suppose a patient receives 8 hour long dialysis now. First the water in the blood is removed. Then the water in the extravascular space shifts into the blood and it is also removed.
Suppose the patient drinks a lot of water after the dialysis. First the water is absorbed into the blood. Then the extra water shifts into the extravascular space. Since the water in the extravascular space has been removed fully by the long dialysis, there is enough room to store water there. So the blood does not become full of water. Hence hypertension does not occur.
The Second Reason: Suppose a patient receives 8 hour long online HDF with a blood flow of 600 ml/min, a pre-dilution flow of 24 L/h, a dialysate flow of 700 ml/min and 2.5 square meter dialyzers.
First the toxins in the blood are removed quickly. Then the toxins in the extravascular space shift into the blood. Since the osmotic pressure in the extravascular space becomes lower, the water in the extravascular space shifts into the blood and is removed. So there is even more room to store water in the extravascular space.
The Third reason: If the blood glucose is 400 mg/dl, patients feel thirsty. If it is 80 mg/dl, they do not.
On long online HDF with a high blood flow, BUN is close to 20 mg/dl even before dialysis. The osmotic pressure is low. So they do not feel thirsty. Since they drink little, the water in the blood does not increase. Thus hypertension does not occur.
ABH-F and ABH-P have been developed for use as hemodiafilters in hemodiafiltration (HDF) therapy. We evaluated the solute removal characteristics of the ABH-F and ABH-P during pre-dilution HDF (pre-HDF) and post-dilution HDF (post-HDF) under various operating conditions during an in vitro study, using bovine blood.
The dialyzer was operated at 310 K, a Q B of 250 mL/min, a dialysate flow rate (Q D ) of 500 mL/min, and a net filtration flow rate (Q F ) of 31.2, or 62.5 mL/min and regulated by a dialysis machine during post-HDF (post-Q F 31.2 and post-Q F 62.5) or at a Q B of 250 mL/min, Q D of 500 or 250 mL/min, and Q F of 62.5 or 250 mL/min during pre-HDF (pre-Q F 62.5 and pre-Q F 250).
In both pre-and post-HDF experiments, the initial TMP values increased with an increase in Q F because of the increasing filtration fraction; the TMP value gradually increased with time because of membrane fouling due to protein deposition on the membrane. The TMP value of ABH-F was higher than that of ABH-P under identical Q F conditions. The creatinine clearance (CL) during pre-HDF was approximately 85% of that during post-HDF; this difference was attributed to the decreasing concentration difference between blood and dialysate sides due to dilution of the supplementation fluid. On the other hand, the initial CL of β 2 -microglobulin and α 1 -microglobulin increased with increasing Q F , and these CL values slightly and steeply decreased, respectively, with time due to membrane fouling. Under identical Q F conditions, post-HDF has higher TMP and CL values as compared to pre-HDF because of a higher solute concentration profile on the blood side. All CL values of ABH-P were higher than that of ABH-F under identical flow rates. The creatinine CL values of ABH-P-post-Q F 62.5, the β 2 -microglobulin CL values of ABH-P-pre-Q F 250, and the α 1 -microglobulin CL values of ABH-P-post-Q F 62.5 had the maximum values under the all conditions. The β 2 -microglobulin and α 1 -microglobulin CL values of ABH-P-post-Q F 62.5 were 0.92 and 1.87 times the values of ABH-P-pre-Q F 250, respectively. The post-Q F 62.5 showed high solute removal, and the pre-Q F 250 showed high removal in middle molecular.
Adequate operating conditions using ABH-F and ABH-P should be determined for each dilution mode in HDF treatment. The number of extremely long-term survivors of hemodialysis patients has been increasing. We examined characteristics of such patients.
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Characteristics of Patients Receiving Extremely Long Term Hemodialysis Therapy
Methods: Seventy outpatients receiving maintenance hemodialysis were enrolled in this study. We classified the patients according to the duration of hemodialysis therapy (10>years (n = 34), 10-20 years (n = 9), 20-30 years (n = 9), or 30 < years (n = 18)) and compared them. Clinical information were collected from the patient records. The muscle mass was assessed by measuring the mid-upper arm muscle area (AMA). Bone mineral density (BMD) was assessed using dual-energy X-ray absorptiometry scans. The absolute BMD values for the 1/3 distal radius on the side not containing the vascular access were reported.
Results: The mean age of the patients at the start of dialysis therapy was 30.5 ± 7.7 years in the 30 < group, and younger than that of other groups (P < 0.001 versus 10>group, P < 0.001 versus 10-20 group, p = 0.024 versus 20-30 group). The cause of the renal failure was chronic glomerulonephritis in all the cases of the 30 < group. Hypertension was observed in 55.6% of the 30 < group but in 97.1% of the 10>group (P < 0.001). Hepatitis C virus (HCV) antibody was positive in 27.8% of the 30 < group but in 0% of the 10>group (p = 0.001). No significant differences in total protein, albumin, total cholesterol, triglyceride or C-reactive protein levels were observed among 4 groups. The body mass index (BMI) was significantly lower in the 30 < group than in the 10>group (19.6 ± 2.3 kg/m 2 versus 22.0 ± 4.5 kg/m 2 , p = 0.028). The AMA was significantly lower in the 30 < years group than in the 10>group (33.2 ± 6.3 cm 2 versus 42.6 ± 10.7 cm 2 , P = 0.002). The BMD was significantly lower in the 30 < group than in the 10>group (0.431 ± 0.132 g/cm 2 versus 0.618 ± 0.164 g/ cm 2 , P < 0.001). Seventeen (94.4%) patients had undergone operation for carpal tunnel syndrome, and 7 (38.9%) had undergone surgery for cervical destructive spondyloarthropathy in the 30 < group.
Conclusions: Patients on hemodialysis for more than 30 years were young at the start of hemodialysis. All of their causes of renal failure were chronic glomerulonephritis. Hypertension was not so common. Positive rate of HCV antibody was relatively high. The BMI, AMA and BMD were reduced, whereas nutritional markers such as the total protein, albumin, total cholesterol and triglyceride levels were preserved. Hemodialysis-associated amyloidosis was common among them.
30th Annual Meeting of the International Society of Blood Purification (ISBP) Abstracts HMIMV-Rabat between January 2010 and December 2011. We analyzed the epidemiological, clinical, paraclinical, therapeutical and evolutionary features.
Results: Forty-one chronic hemodialysis patients are admitted for infectious syndrome. Tuberculosis there is 14.6%. These 6 patients, 4 women and 2 men, were aged 51.16 years in average. The length of dialysis was 53.5 months. Fever was present in 2 cases, leukocytosis in 4 cases and elevated CRP in all cases. The tuberculin skin test was positive in one case and Mycobacterium tuberculosis isolated from one another. Usual radiographs and CT scans were performed in all patients and were in favor of tuberculosis. Histological evidence was obtained in 3 cases. The locations were found ganglion (2 cases), peritoneum (2 cases), pleuropulmonary (1case) and bone (1 case). The complications observed were due to anti bacillary treatment (2 cases of elevated transaminases, one case of confusion). The outcome was favorable in 5 patients and fatal in one patient.
Conclusions: TB is more common in hemodialysis. It occurs especially during the first 2 years of hemodialysis. The telltale signs are nonspecific. The location is especially extra-pulmonary. The prognosis is closely related to early diagnosis and treatment.
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Tacrolimus-Associated Diabetes Mellitus in Post Renal Transplantation
Mohamed El Amrani, Driss Kabbaj, Mohammed Benyahia
Military instruction hospital Mohammed V, Morocco
Introduction: Medical advances in renal transplantation are constantly evolving. But several complications remain worrisome and engage the patient and the graft survival.
Materials and Methods: Retrospective study including ten nondiabetic renal transplant patients put under induction protocol based on basilixumab and corticosteroids, and maintenance with tacrolimus, mycofenolate mofetil and corticosteroids. Patients with high fasting blood glucose requiring antidiabetic therapy were studied.
Results: Five patients developed de novo diabetes one month after transplantation. They were four men and a woman aged 39.8 years on average. HCV PCR was negative in all patients. The biological monitoring showed an overdose of tacrolimus. The dose adjustment of tacrolimus, early cessation of corticosteroid therapy and the use of temporary oral antidiabetic (OAD) allowed the normalization of blood glucose levels in these patients, and the subsequent interruption of OAD.
Conclusion: Screening for diabetes should be regular after transplantation and immunosuppressive strategy reconsidered if risk factors are found.
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Cardiac Method: This is a retrospective cohort study involving 24 hemodialysis patients with left ventricular dilatation and systolic dysfunction (diastolic left ventricular diameter>55 mm and ejection fraction < 50%), who were admitted to our hospital from November 2007 to October 2009. The prevalence of antibodies against β1-adrenergic receptors, M2 muscarinic acetylcholine receptors and myosin were examined using ELISA.
Results: Nine patients (38%) were positive for the antibody against β1-adrenergic receptors, 8 (33%) for M2 muscarinic acetylcholine receptors, and 7 (29%) for myosin. Twelve patients (50%) had at least one of these antibodies. Thirteen patients died during the mean observation period of 25 months, and one-year survival rate was 83%. The age-adjusted hazard ratio for mortality was 1.70 (95% CI: 0.50-5.76, p = 0.4) in β1-adrenergic receptors, 0.97 (95% CI: 0.30-3.15, p = 0.9) in M2 muscarinic acetylcholine receptors, and 1.35 (95% CI: 0.36-5.10, p = 0.7) in myosin positive group.
Conclusion: A half of dialysis patients with left ventricular dysfunction had cardiac autoantibodies. Those who had antibodies against β1-adrenergic receptors or myosin tended to have higher mortality, although the difference was not statistically significant. 
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Tuberculosis in Chronic Hemodialysis
Military instruction hospital Mohammed V, Morocco
Introduction: Chronic uremia exposes to a high risk of infectious complications in particular tuberculosis.
Materials and Methods: Retro and prospective study including all chronic hemodialysis patients presenting tuberculosis from chronic hemodialysis patients admitted for infectious syndrome in the department of nephrology dialysis and kidney transplantation in Introduction and Aims: LC, a non-calcium containing phosphate binder, is widely prescribed in dialysis patients with hyper-
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The Efficacy of Interventional Radiology for Gastrointestinal Bleeding in Hemodialysis Patients Masataka Banshodani, Hideki Kawanishi, Misaki Moriishi, Sadanori Shintaku, Rika Ago, Nanako Mashima, Kazuya Maeda, Tomoyasu Sato, Shinichiro Tsuchiya Tsuchiya General Hospital, Hiroshima, Japan Background and Objectives: The incidence of gastrointestinal bleeding in hemodialysis patients is higher as compared with healthy people, and is often lethal. We have evaluated the efficacy of Interventional Radiology (IVR) for gastrointestinal bleeding in Hemodialysis patients.
Methods: Between January 2006 and June 2012, 8 hemodialysis patients with gastrointestinal bleeding were treated by the IVR (mean age, 64.3 years). One of 8 cases was duodenal bleeding, 2 were jejunal bleeding, 1 was ileocecum bleeding, 2 was ascending colon bleeding, and 2 were sigmoid colon bleeding. In all cases, blood transfusions were frequently needed. After examinating the site of bleeding by endoscopy or contrast-enhanced computed tomography (CT), embolizations were performed by the IVR using coil, spongel, or histoacryl.
Results: Six of 8 patients with gastrointestinal bleeding were successfully salvaged by the IVR. The remaining two died after IVR. In one case, the duodenal bleeding was refractory to endoscopic treatment. The embolizations were performed twice, but the patient died of the embolization-site aneurysm rupture 24 days after the embolizations. In the other case, massive jejunal bleeding and disseminated intravascular coagulation (DIC) were identified at the time of the first examination, and the patient died of multiorgan failure 26 days after the embolization.
Treatment Strategy: From our experience, we established a treatment strategy for hemodialysis patients with gastrointestinal bleeding. In massive bleeding cases, we immediately identify the site and degree of bleeding with contrast-enhanced CT and make early treatment by the IVR.
Conclusions: The incidence of gastrointestinal bleeding in hemodialysis patients is higher as compared with healthy people, and is often lethal. In such cases, to make sure the site and degree of bleeding with contrast-enhanced CT immediately and make early treatment by the IVR are important. Abstracts dialysis time. The phosphate intake (805 ± 283 mg/day) obtained through dietitian interviews of patients roughly agreed with that (839 ± 260 mg/day) calculated with the above formula.
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Interobserver Background: Hemodialysis patients have an increased risk of developing atherosclerosis. Because many hemodialysis patients are treated at outpatient clinics in Japan, simple and effective screening strategies for identifying high-risk patients in routine clinical practice are important and desired. Checking diagonal ear lobe crease (ELC) may have potential as a useful and cost-free method of identifying high-risk patients, because ELC has been characterized in the literature as a surrogate marker which can identify high risk patients having occult atherosclerosis. However, to our knowledge, there is no previous report about the usefulness of ELC among hemodialysis patients. In addition, conflicting results have been reported regarding the predictive value of ELC in cardiovascular disease. While many previous literatures have showed that presence of ELC is one of the independent risk factors for cardiovascular disease, some reports have failed to show this association. We hypothesized that the conflicting results would come from different evaluation of ELC, because interobserver reliability has not been assessed. The aim of this study was to evaluate interobserver reliability of ELC as a methodological basis for examining the relationship between ELC and cardiovascular diseases among hemodialysis patients.
Methods: A cross-sectional study was conducted among hemodialysis patients aged 20 years or older. Bilateral earlobes of participants were photographed in the spine position during a dialysis session by one researcher (M.W.) using a digital camera. Presence of ELC was defined according to previous studies. Two experienced nephrologists (J.J.K. and K.K.) blinded to the clinical characteristics of participants reviewed the photos independently. The agreement between the two nephrologists was calculated in percent and as the kappa statistic as a marker of agreement beyond chance.
Results: Among the 207 hemodialysis patients studied, 57% were men, median dialysis vintage was 9 years (range; 2 months to 42 years), and 30% had a history of cardiovascular diseases. The most common primary cause of end-stage renal disease was chronic glomerulonephritis (48%). The interobserver agreements for ELC were moderate (agreement 86%; the kappa statistics = 0.67, 95% confidence interval, 0.56-0.78).
phosphatemia. LC has been reported to be effective in controlling hyperphosphatemia without calcium overload. However, intestinal residual of LC, which is a transitional metal and is opaque to X-rays, was reported to interfere in BMD measurements with DEXA (Am J Nephrol 32:425,2010).
Methods: We retrospectively examined effect of LC use on BMD measurements of lumbar bone (L3-5) and radius (distal 1/3) with DEXA among long-term HD patients with hyperphosphatemia.
Results: Total 39 patients on long-term HD (age 59.6 ± 10.5 years, female 17.9%, HD vintage 11.2 ± 4.9 years, diabetes 38.5%) were reviewed. LC significantly reduces serum phosphate and parathyroid levels. Abdominal X-rays showed high density-material in gastrointestinal tract among most patients (76%). Lumbar BMD abruptly increased over 30% in 31.8% patients after LC administration. However, BMD of distal 1/3 radius did not change in all patients with LC. Changes in T and Z score of lumbar bone were significanly higher in patients with LC compared with control subjects without LC.
Conclusions: Lumbar BMD measured with DEXA might be overestimated in patients with LC, because of intestinal LC residual.
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A Formula to Calculate Phosphate Intake of Hemodialysis Patient Akihito Tanaka, Takahiro Shinzato, Kenji Maeda Daiko Medical Engineering Research Institute, Nagoya, Japan
We developed a formula to calculate phosphate intake from serum phosphate levels before and after hemodialysis (HD). First, we made a formula to calculate the amount of phosphate removed by HD under the following assumptions: (1) the serum phosphate level decreases exponentially for two hours after the start of HD, and then stays at the same level until the completion of HD; (2) the phosphate clearance in the dialyzer is calculated from the dialyzer KoA for phosphate, the blood flow rate, and the dialysate flow rate; and (3) the amount of phosphate removed by HD is calculated by integrating the product of the serum phosphate concentration and the phosphate clearance of the dialyzer from the start to end of HD.
Next, an experienced dietitian prepared a precise menu for each patient, referring to the content of the patient's ordinary meals, and using ingredients for which the phosphate content is known. The patient or a family member then prepared meals in strict accordance with that menu. In this case the patient's phosphate intake was considered to be equal to the amount of phosphate contained in the menu prepared by the dietitian.
Finally, the relationship between the amount of phosphate removed by dialysis and the daily phosphate intake were obtained on a total of 16 occasions for 6 anuric HD patients.
The results showed a high correlation between the amount of phosphate removed by dialysis (x) and the daily phosphate intake (y): y = 0.5055x-12.577 (r = 0.89). Since the correlation coefficient was sufficiently high, the above formula can be used to calculate phosphate intake from the amount of phosphate removed by dialysis, which is calculated from serum phosphate levels before and after dialysis, KoA for phosphate, blood flow rate, dialysate flow rate, and 30th Annual Meeting of the International Society of Blood Purification (ISBP) nosuppressant use and processed plasma volume at the time of PEx showed no association (p = 0.24, 0.29 and 0.62, respectively).
Conclusion: Higher incidence of allergic reaction at initiation of PEx was observed in younger patients and lower incidence of allergic reaction was observed in patients with hepatic failure. Administration of immunosuppressants including steroids before the initiation of PEx revealed no beneficial effect for prevention of allergic reactions.
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High Flow-Volume PMMA Hemodialfiltration Therapy and Diuresis in Patients with Necrotizing Severe Acute Pancreatitis Complicating Acute Kidney Injury
Tetsuya Makiishi, Sayako Maeda
Otsu Red Cross Hospital, Otsu, Japan Backgrounds: Current clinical practice guidelines recommend aggressive fluid resuscitation in the early management of severe acute pancreatitis (SAP). When acute kidney injury (AKI) accompanies SAP, however, it may cause overhydration leading to lethal outcome. Recently, potential benefits of high flow-volume PMMA hemodialfiltration (HDF) therapy as a non-renal indication for SAP has been reported. We experienced 4 cases of patients with nectrotizing SAP (NSAP) accompanying AKI treated with this blood purification therapy.
Purpose: To investigate the effect of high flow-volume PMMA HDF therapy on diuresis in patients with NSAP complicating AKI.
Study Design: Case series. Methods: We report 4 cases of patients who were treated with high flow-volume PMMA HDF therapy as a non-renal indication for NSAP for 3 consecutive days after the diagnosis in addition to the conventional therapy including vigorous fluid resuscitation and continuous regional arterial infusion of nafamostat mesilate and meropenem at our institution between 2009 and 2011. Their clinical characteristics and courses were collected and examined for analysis. The data from patients with NSAP (n = 4) treated with the conventional therapy alone at our institution before 2009 were collected and used as references.
Results: All 4 cases and 4 reference cases were discharged alive. The 4 cases were on average critically ill compared to the reference cases at the time of admission (APACHE II score; 14 ± 3 vs. 9 ± 3, creatinine; 2.6 ± 1.5 mg/dL vs. 1.3 ± 0.6, SAP score; 5 ± 2 vs. 4 ± 0, respectively). The length of days between the admission and the day when daily urine volume exceeded infusion volume for the first time after the admission was 3.8 ± 1.0 for the cases and 4.5 ± 1.3 for the reference cases despite that daily infusion volume on average was not different between them. As a result, cumulative water balance (infusion volume minus urine volume) for the first week after the admission was 7.5 ± 4.3 L for the cases and 10.1 ± 2.5 L for the reference cases, respectively. Levels of IL-6 did not show significant change before and after the HDF therapy.
Conclusion: These observations raise the hypothesis that high flow-volume PMMA HDF therapy prompts diuresis in patients with NSAP complicating AKI during the initial aggressive fluid replacement therapy.
Conclusion: Despite the lack of a theoretical foundation for the relationship between ELC and atherosclerosis, the satisfactory agreement in this preliminary study may indicate that checking ELC in routine clinical practice to detect high-risk patients would be promising, and motivates further studies.
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Incidence of Allergy-Associated Discontinuation of Plasma Apheresis Mikako Hisamichi, Masato Oroku, Kayori Tsuruoka, Hiroo Kawarazaki, Tsutomu Sakurada, Sayuri Shirai, Yugo Shibagaki, Takashi Yasuda, Kenjiro Kimura Division of Nephrology and Hypertension, Department of Internal Medicine, St Marianna University School of Medicine, Kawasaki, Japan Allergic reactions at initiation of plasma exchange: a single center study Background: Plasma exchange (PEx) is an important procedure as a treatment for a variety of severe diseases such as fulminant hepatitis in Japan. However, PEx can cause allergic reactions which may influence treatment outcome.
Purpose: To clarify the frequency of allergic reactions related to initial PEx and to evaluate factors involved in the incidence of allergic reactions.
Patients and Methods: This study was a retrospective study at a single center. We investigated patients in whom PEx were performed at St. Marianna University School of Medicine Hospital from March 2002 to February 2012. Information of the PEx procedure and patient's characteristics were obtained from their clinical records. Primary endpoint was the incidence of allergic reactions related to PEx at initiation. We expressed the severity of allergic reactions in three levels: mild, no need for treatment; moderate, treatment needed but not life threatening; severe, treatment needed and life threatening. Indications for PEx were classified into five categories; procedure before ABO incompatible kidney transplantation (n = 14), hepatic failure (n = 18), rheumatic diseases (n = 36), thrombotic microangiopathy (n = 21), and other diseases (n = 4).
Results: Plasma exchange was performed in 93 patients (37 men, 56 women). Mean age was 56 years (range from 10 to 87 years). Twenty-five (27%) allergic reactions occurred during the procedure; 8 (9%) were mild, 11 (12%) were moderate and 6 (6%) were severe. Prior to PEx, 66 patients (71%) were administered steroids and 26 patients (28%) were administered immunosuppressants as treatment for the indicative disease. Mean dose of steroids at the time of PEx was 20 mg as prednisolone. Twenty-seven (29%) had past history of blood transfusion and 29 (31%) had past history of allergic diseases. Factors related to the incidence of allergic reactions was younger age (p = 0.01), and patients with hepatic failure showed a significantly lower incidence (p = 0.02). However, the severity of allergic reaction had no relation with age or disease. Prior steroid treatment, immu-30th Annual Meeting of the International Society of Blood Purification (ISBP) and thus could protect against the harmful effect possibly caused by excessive iron store in body.
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In Vitro and Clinical Evaluation of Hemofilter 
